Interplay of genetic and environmental triggers in intestinal inflammation : Genetics and transcriptomics in celiac disease and inflammatory bowel disease by Parmar, Amarjit Singh
1 
 
 
 
 
 
Interplay of genetic and environmental triggers in 
intestinal inflammation: Genetics and transcriptomics 
in celiac disease and inflammatory bowel disease 
 
 
 
 
AMARJIT SINGH PARMAR 
Research Programs Unit, Immunobiology  
University of Helsinki, Helsinki, Finland 
 
 
 
 
ACADEMIC DISSERTATION 
To be presented with the permission of the Faculty of Medicine, University of Helsinki,  
for public examination in Lecture Hall 1, Haartman Institute, Haartmaninkatu 3, Helsinki,  
on August 2nd 2013, at 12 noon 
 
 
Helsinki 2013 
  
2 
 
SUPERVISED BY 
Päivi Saavalainen, PhD, Docent 
Academy Research Fellow 
Research Programs Unit, Immunobiology 
University of Helsinki, Helsinki, Finland 
Elisabet Einarsdottir, PhD, Docent 
Research Programs Unit, Immunobiology 
University of Helsinki, Helsinki, Finland  
 
REVIEWED BY  
Hannu Turpeinen, PhD, Docent 
Institute of Biomedical Technology 
University of Tampere, Tampere, Finland 
and, BioMediTech, Tampere, Finland 
 
Kaija-Leena Kolho, M.D, Ph.D, Docent 
Children’s Hospital, Helsinki University Central Hospital 
University of Helsinki, Helsinki, Finland 
 
OPPONENT 
Ross McManus, PhD 
Professor in Molecular Medicine 
Institute of Molecular Medicine 
Department of Clinical Medicine 
Trinity Centre for Health Sciences 
St James's Hospital 
James's St, Dublin 8, 
Ireland 
 
 
 
 
ISBN 978-952-10-9008-0 (paperback) 
ISBN 978-952-10-9009-7 (PDF) 
http://ethesis.helsinki.fi 
Unigrafia, Helsinki 2013 
  
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TO MY FAMILY 
 
 
 
 
Our greatest weakness lies in giving up. The most certain  
way to succeed is always to try just one more time. 
Thomas A. Edison 
 
If you're going through hell, keep going. 
Winston Churchill 
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Abstract 
Celiac disease (CelD) and inflammatory bowel disease (IBD) [comprising Crohn’s disease (CD) and 
ulcerative colitis (UC)] are chronic inflammatory diseases of the gastrointestinal (GI) tract. In CelD, 
the disease triggering environmental factors are gluten peptides, derived from wheat, rye or barley. 
The genes within the human leukocyte antigen (HLA) region on chromosome six encoding HLA-DQ2 
and –DQ8 heterodimers are strongly associated with CelD. However, in both IBD and CelD, non-HLA 
genes have been identified and some genes confer susceptibility to both CelD and IBD suggesting 
shared genetics in disease etiology. No definite environmental factors in IBD are known, but IBD is 
thought to be precipitated by inappropriate innate and adaptive immune response towards host gut 
microbiota. The fucosyltransferase 2 (FUT2) gene controls the expression of A-, B- and H- blood 
group antigens in mucus and other body secretions. Homozygosity for a nonsense mutation 
(rs601338G>A) in the FUT2 gene leads to the absence of ABH blood group antigens (non-secretor 
status). The secretor status affects the composition of gut microbiota which is important for proper 
development of the mucosal immune system. Thus, genetic variations in this gene may confer 
susceptibility to CelD and IBD. This study was conducted to identify genes which are affected by 
environmental factors (gliadin peptides) and to identify genes which affect environmental factors 
(gut microbiota) and also to explore the shared genetic background of CelD and IBD.  
In Study I, the DNA microarray chips were used to study the effects of pepsin and trypsin (PT) 
digested gliadin (PT-G) and a synthetic gliadin peptide p31-43 on Caco-2 cell gene transcription. A 
blank PT control served as a negative control. Compared to the untreated medium control (MED-
CTL), the expression of 1705 and 211 probes was affected by PT-G, and p31-43 respectively. The 
differential expression of three PT-G affected genes was confirmed by qRT-PCR. However, these 
genes were also affected by PT containing negative controls used in the study, suggesting a novel, 
non-enzymatic role for pepsin- and trypsin- derived peptides in Caco-2 gene regulation. The 
expression of the two genes differentially expressed after treatment with gliadin p31-43 peptide was 
also verified by qRT-PCR. No difference in gene expression in p31-43 peptide treated cells compared 
to the untreated control cells or the negative control was observed. This study concludes that the 
effects of gliadin peptides on enterocyte gene expression may be marginal. The presence of other 
cell types or chemical mediators may be required for the previously reported effects of gliadin in 
CelD. 
In Study II, the association of rs601338-A-FUT2 with CelD, CelD patients with dermatitis 
herpetiformis (DH) denoted (CelD + DH), CD, UC and IBD was investigated in the Finnish population. 
The SNP rs601338 was genotyped in 1045 controls, 943 CelD patients, 119 DH patients, 303 CD 
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patients and 545 UC patients. The association analyses were performed using PLINK version v1.07. 
The FUT2 non-secretor genotype (rs601338-AA) was associated with increased risk for CelD. In 
addition, rs601338-A showed a nominal recessive association with CelD.  The rs601338 SNP did not 
associate with DH, but showed significant association with CelD + DH. The rs601338 SNP did not 
associate with CD, but rs601338-A showed significant association with UC under the dominant 
association model. It is concluded that the FUT2 non-secretor status (rs601338-AA) is associated 
with increased risk for CelD but not IBD in the Finnish population. 
In Study III, the association of novel CelD risk markers with IBD in the Finnish and Swedish 
populations was investigated. Forty-five CelD associated SNPs were genotyped in 699 Finnish IBD 
(CD: 240 and UC: 459) and 2482 control subjects. The Swedish dataset comprised 923 UC patients 
and 341 controls. The association of these SNPs with different subphenotypes of IBD was also 
investigated. Meta-analyses on Finnish and Swedish UC datasets were also performed. Several CelD 
risk SNPs were associated with CD and/or UC. Six SNPs each were associated with CD and UC and 
two SNPs (rs1893217-PTPN2 and rs4819388-ICOSLG) were associated with both forms of IBD. Seven 
CelD risk alleles were protective (OR < 0.90) and 23 risk alleles conferred higher risk (OR > 1.10) for 
CD or UC. Twenty-two and 17 SNPs associated with a CD- or UC-specific subphenotype and 11 SNPs 
associated with both CD and UC subphenotypes. The SNP rs6974491-A-ELMO1 showed strong 
evidence for association with early-onset UC (onset age: 0-18 years) whereas rs2298428-T-UBE2L3 
associated with early-onset CD (onset age: 0-18 years) and also with non-stricturing non-penetrating 
phenotype of CD. In the Finnish and Swedish UC meta-analysis, seven SNPs were significantly 
associated with UC. In the Finnish-Swedish UC subphenotype meta-analysis, nine SNP markers 
associated with one or more UC subphenotypes. The SNP rs1738074-A-TAGAP showed an 
association with familial UC whereas rs4819388-G-COSLG associated with sporadic UC. The CelD risk 
SNP rs6974491-A-ELMO1 associated with early-onset UC. Based on these results, it is thus concluded 
that several CelD risk SNPs are associated with CD and/or UC or their associated subphenotypes in 
the Finnish and Swedish populations. 
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Introduction 
Celiac disease (CelD) and inflammatory bowel disease (IBD) are inflammatory diseases of the 
gastrointestinal (GI) tract which can affect an individual of any age. Both are regarded as complex 
diseases because of the involvement of multiple genes and environmental factors in disease onset 
and progression. The complexity of the disease increases several fold when unequal contribution of 
genes and/or environmental factors over a long time is taken into account. The environmental 
trigger in CelD is dietary gluten, whereas environmental factors which trigger the onset of IBD are 
largely unknown. The use of different genetic approaches (linkage studies and association studies) 
has led to the identification of several risk loci in CelD and IBD (Koskinen et al. 2008, Duerr et al. 
1998, Hampe et al. 1999b, King et al. 2000, Dubois et al. 2010, Jostins et al. 2012). Linkage studies 
are effective in identifying rare causal mutations which are enriched in the family, whereas 
association studies present an effective way to identify common genetic variants that are enriched in 
disease affected, but unrelated, individuals. However, considering the small effect size that many 
genes are thought to have in complex diseases, such an approach require a great number of 
samples. This limitation is usually overcome by combining datasets derived from different 
populations and performing a meta-analysis (Dubois et al. 2010, Anderson et al. 2011, Franke et al. 
2010). Recent research suggests that different immunological diseases share susceptibility genes 
(Festen et al. 2011, Zhernakova et al. 2011, Coenen et al. 2009). Many of the shared genes have 
important functions in the regulation of immune responses in disease pathogenesis. Studies 
investigating the common genetic background of different immunological diseases have furthered 
our understanding of shared disease pathogenesis (Zhernakova, van Diemen & Wijmenga 2009, 
Cotsapas et al. 2011). Nevertheless, despite advances made in identifying susceptibility genes in CelD 
and IBD, no cure for these diseases is yet available and the symptoms are treated through different 
approaches.  
The purpose of this thesis was to investigate interactions between genes and environment in CelD 
and IBD and to explore the shared genetic background between these diseases. How the 
environmental trigger in CelD (i.e. gluten) affects epithelial cell gene transcription was investigated. 
Furthermore, the association of a genetic polymorphism in the fucosyltransferase 2 (FUT2) gene with 
CelD and IBD in the Finnish population was tested. Shared genetics between CelD and IBD was also 
investigated by studying the association of novel CelD associated risk loci in IBD cohorts from Finland 
and Sweden. 
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Review of the literature 
1. The immune system at a glance 
In everyday life, the human body is exposed to numerous potentially harmful environmental factors, 
living or nonliving, which can cause serious pathologies. Our immune system is however apt at 
providing adequate protection from such elements. In healthy individuals the two branches of the 
immune system, the innate immune system and the adaptive immune system, work in concert to 
protect the body from various threats.  
1.1. Innate immunity 
The immediate protection against pathogens is provided by innate immunity mediated by natural 
killer (NK) cells, mast cells, eosinophils, basophils, neutrophils, macrophages and dendritic cells. 
These are also known as the cells of the innate immune system. The first line of defense is however 
provided by epithelial cells which line the body cavities. The epithelial cells are interconnected 
through tight junctions and form a physical barrier against foreign antigens. Macrophages are tissue 
resident phagocytic cells which can recognize, ingest and destroy pathogens. When macrophages, 
through their cell surface receptors, interact with pathogens they are induced to synthesize and 
secrete cytokines and other chemical mediators. These molecules create a state of inflammation at 
the infection site. Inflammation recruits other effector cells to the infection site to clear the infection 
and also serves as a physical barrier to prevent further spread of the infection (Janeway et al. 2001). 
Neutrophils are also phagocytic cells which are present in large numbers in the blood but migrate to 
the site of infection during an innate immune response. Immature dendritic cells are present in 
different tissues throughout the body and bear receptors that recognize common features of many 
pathogens (Janeway et al. 2001, Underhill, Goodridge 2012). Dendritic cells and neutrophils help in 
the phagocytosis of invading pathogens. The innate immune response is non-specific and responds 
to different pathogens in much the same way. It does not generate immunological memory and a 
response to recurrent infections with the same pathogen is always the same. Although the innate 
immune system is highly effective in preventing the establishment of an infection, it falls short some 
times. This is primarily due to different mechanisms the pathogens have evolved to evade detection 
or destruction by the innate immune system. Only when the innate immune system fails to control 
the infection is the adaptive immune response initiated.  
 
 
13 
 
1.2. Adaptive immunity 
An adaptive immune response comprises T-cell mediated immunity and humoral immunity. In 
contrast to the quick but non-specific nature of the innate immune system, adaptive immunity is 
highly specific. It also generates immunological memory, thus subsequent responses to infection 
with the same pathogen are rapid. However, T cells are unable to bind and respond to pathogens on 
their own and require presentation of small pathogen-derived peptides (antigens) by other cells for 
their activation. Tissue dendritic cells are known as professional antigen presenting cells (APCs) 
which specialize in taking up antigens and activating naive T cells (Janeway et al. 2001). Although less 
potent, macrophages and B cells are also able to present antigens to T cells.  
When dendritic cells recognize and ingest microbial antigens during innate immune response, they 
are stimulated to express co-stimulatory molecules on their cell surface and to migrate to local 
lymphoid tissues. Here, the microbial antigens are presented to antigen-specific naive T cells 
complexed with either the major histocompatibility complex (MHC) class I or class II molecules. The 
antigens that bind to MHC class I molecules are generally virus-derived cytosolic peptides or self-
peptides. These antigens are presented to naive T cells which express co-receptor protein CD8 (CD8+ 
T cells) on their cell surface. The peptides generated in acidic endocytic vesicles are complexed with 
MHC class II molecules and presented to CD4 co-receptor expressing T cells (CD4+ T cells). The MHC 
region is highly polymorphic and during development T cells are selected for recognizing foreign 
peptides bound to self-MHC molecules only. An APC must express co-stimulatory molecules and 
present antigens complexed with MHC molecules to fully activate T cells. Antigen presentation by 
APCs in the absence of co-stimulatory molecules results in T-cell tolerance. After activation, CD8+ T 
cells differentiate into cytotoxic T cells and specifically target infected cells for killing. The CD4+ T 
cells however differentiate into type-1 T helper (Th1) cells, Th2 cells, Th9 cells, Th17 cells, regulatory 
T (Treg) cells or follicular helper T (Tfh) cells (Dardalhon et al. 2008, Vinuesa et al. 2005). All the 
subsets of CD4+ T cells participate in different aspects of the host adaptive immune system.  
1.2.1. Th1 and Th2 cells and their role in autoimmune diseases 
The differentiation of CD4+ T cells into functionally distinct Th1 and Th2 cells, each with a specific 
cytokine profile, was described by Mossman et al. (Mosmann, Coffman 1989) in 1989. When Th1 
cells are stimulated they produce large amounts of interferon gamma (IFN-γ) and also tumor 
necrosis factor (TNF)-α and interleukin-2 (IL-2) (Dardalhon et al. 2008, Roberts-Thomson et al. 2011). 
The CD4+ Th1 cells are primarily involved in protection against intracellular pathogens through 
macrophage activation and facilitate delayed-type hypersensitivity reactions and the production of 
selected antibodies. In contrast, Th2 cells have a prominent role in allergic responses and are 
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characterized by the production of cytokines such as IL-4, IL-5, IL-13 and IL-25 (Dardalhon et al. 
2008). Th2 cells participate in the elimination of parasites and extracellular pathogens through the 
induction of B-cell isotype switching to IgE and IgG and antibody production. The differentiation of 
Th1 cells is promoted by APC-derived IL-12 but inhibited by IL-4 which is a Th2 cell-specific cytokine. 
Similarly, IFN-γ inhibits the differentiation and effector functions of Th2 cells (Roberts-Thomson et al. 
2011, Liblau, Singer & McDevitt 1995).  
The Th1 subset of CD4+ T cells was long believed to be largely responsible for the development of 
many autoimmune diseases (Liblau, Singer & McDevitt 1995). Studies on animal models for human 
autoimmune diseases showed the presence of Th1 cell-specific cytokines in the affected tissue at the 
peak of the disease and the presence of Th2 cell-specific cytokines during the recovery phase (Liblau, 
Singer & McDevitt 1995, Khoury, Hancock & Weiner 1992). The ability of adoptive transfer of Th1 
cells to induce the disease in genetically susceptible mice (Baron et al. 1993) and disease prevention 
by anti-INF-γ antibodies (Campbell et al. 1991) or by the systemic administration of IL-4 (Rapoport et 
al. 1993) further strengthened this notion. Subsequently, it was shown that the reduction of IFN-γ 
signaling or a lack of other molecules critical in Th1 cell differentiation does not protect mice from 
experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS), but 
results in a more severe disease (Dardalhon et al. 2008, Ferber et al. 1996). These studies suggested 
the existence of another type of effector T cell in organ-specific autoimmunity.  
1.2.2. Th17 cell subset and autoimmunity 
Interleukin-12 is composed of two subunits, p35 and p40, with the p40 subunit being shared with 
another cytokine, IL-23. The IL-23 cytokine consists of the IL-23p40 and IL-23p19 subunits and is 
produced predominantly by macrophages and dendritic cells. Cua el al. showed that mice which lack 
the IL-23 p40 or p19 subunits are resistant to EAE development, but those that lacked the IL-12 p35 
subunit are not (Cua et al. 2003). They suggested that IL-23, rather than IL-12 or Th1 cells in general, 
is critical for EAE development and probably also for other autoimmune diseases. It was later found 
that in the presence of transforming growth factor beta (TGF-β) and IL-6, naive CD4+ T cells 
differentiate into a distinct cell type. This newly identified cell type, now known as Th17, expresses 
the IL-23 receptor and produces large quantities of IL-17, IL-17F, IL-6, IL-21,  IL-22 and tumor necrosis 
factor (TNF) (Bettelli et al. 2006). Confirming the pathogenic nature of IL-23-dependent Th17 cells, it 
was shown that passive transfer of Th17 cells into naive mice causes EAE in these mice (Langrish et 
al. 2005). This effect could be partially blocked using anti-IL-17 antibodies and the authors argued 
that other factors induced by IL-23 (IL-6, IL-17F and TNF) are also important in EAE pathogenesis. 
Since their discovery, Th17 cells have been implicated in many autoimmune diseases including 
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asthma and systemic lupus erythematosus (SLE) (Alunno et al. 2012, Costa, Mattana & da Silva 2010, 
Silverpil, Linden 2012). 
1.2.3. Regulatory T cells, Tr-1 cells and Th9 cells 
Another subset of Th1 cells, termed regulatory T (Tregs) cells, has been shown to have a reciprocal 
developmental relationship with Th17 cells (Bettelli et al. 2006). The Treg cells derive from CD4+ T 
cells in the presence of TGFβ alone, unlike Th17 cells which also require IL-6 (Jager, Kuchroo 2010). 
Regulatory T cells express the transcription factor FOXP3 and can be further subdivided into two 
groups, naturally occurring Tregs (nTregs) and induced Tregs (iTregs). Naturally occurring Tregs are 
generated in the thymus and iTregs differentiate from naive T helper cells in the periphery in the 
presence of TGFβ (Jager, Kuchroo 2010). Tregs are important in maintaining self-tolerance and in 
controlling the expansion and activation of autoreactive CD4+ T effector cells. Thus, Tregs play an 
important role in autoimmune pathogenesis. Furthermore, CD4+ T cells exposed to TGFβ and IL-27 
differentiate into Tr-1 cells (Awasthi et al. 2007) while those exposed to TGFβ and IL-4 differentiate 
into Th9 cells (Soroosh, Doherty 2009). In mice, Tr-1 cells do not express Foxp3, but possess strong 
immunosuppressive properties and produce the cytokines IL-10 and IFN-γ (Jager, Kuchroo 2010). On 
the other hand, Th9 cells produce IL-9 and IL-10 cytokines and may play a role in defense against 
certain helminth infections (Jager, Kuchroo 2010) as well as in asthma and allergy (Soroosh, Doherty 
2009). 
1.2.4. Follicular helper T cells 
An adaptive immune response comprises a T-cell mediated immune response and a B-cell mediated 
immune response. The CD4+ T cells and the CD8+ T cells are the dominating cell types in T-cell 
mediated immunity. In contrast, the humoral immune response which protects the extracellular 
spaces of the body is mediated by B cells. In the humoral immune response, B cell-produced 
antibodies cause the destruction of pathogens and prevent their spread to other parts of the body 
(Janeway et al. 2001). However, as T cells require help from APCs for activation, B cells require help 
from Th cells for activation and differentiation into antibody-secreting plasma cells. IFNγ produced 
by Th1 cells stimulates B cells to produce IgG2a class antibodies and Th2 cells-derived IL-4 promotes 
the production of IgE class antibodies. A distinct subset of CD4+ T cells, called follicular helper T (Tfh) 
cells, has been identified (Schaerli et al. 2000). These cells are found in germinal centers, have a 
stable expression of chemokine receptor-5 (CXCR5) and provide help to germinal center B cells 
(Vinuesa et al. 2005, Schaerli et al. 2000). Experiments in mice demonstrate that Tfh cells have a 
distinct gene expression profile compared to Th1, Th2 and Th17 cells (Nurieva et al. 2008). The 
generation of Tfh cells is dependent on signal transducer and activator of transcription (STAT)-3 
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signaling and requires the presence of IL-6 and IL-21. Tfh cells have been implicated in autoimmune 
diseases, but their role is not entirely clear (Vinuesa et al. 2005, Weinstein, Hernandez & Craft 2012). 
2. Celiac disease 
Celiac disease (CelD) or gluten-sensitive enteropathy (GSE) is a chronic immune-mediated disease of 
the small intestine characterized by villous atrophy and crypt cell hyperplasia. CelD is caused by the 
ingestion of dietary gluten and affects genetically susceptible individuals. Patients suffering from 
CelD display a wide spectrum of symptoms, both intestinal and extraintestinal. The symptoms in 
CelD can be treated only by maintaining a strict life-long gluten-free diet (GFD).  
2.1. Epidemiology of celiac disease 
Although the prevalence of CelD is around 1% worldwide, it displays a great variation among 
European countries, ranging from 0.3% in Germany (Reilly, Green 2012) to 2.4% in Finland 
(Mustalahti et al. 2010). In Finland, a significant increase (from 1.03% to 1.99%) in CelD prevalence 
over a 20 year period has been reported (Lohi et al. 2007). In an Italian cohort (3483 study subjects, 
aged 12-65 years), the prevalence of CelD was found to be 5.7 per 1000 individuals (0.57%) (Volta et 
al. 2001). However, when the prevalence was studied after conditioning for age, prevalence in the 
age group 12-25 years (784 individuals) was highest at 10.2 per 1000 individuals (1.02%). In a study 
by Riestra et al. which included 1170 randomly selected subjects from an area in Northern Spain, the 
prevalence of CelD was reported to be 2.6 per 1000 (0.26%) (Riestra et al. 2000). In accordance with 
the high proportion of individuals with European ancestry in the United States, Australia and New 
Zealand, prevalence rates similar to that in Europe have been reported. The prevalence of CelD in 
the United States is close to 1% in the general population (Fasano et al. 2003) with more 
pronounced risk for first-degree and second-degree relatives of CelD patients. In large population 
based studies from Australia and New Zealand, the prevalence of CelD was reported to be 0.4% 
(Hovell et al. 2001) and 1.2% (Cook et al. 2000) respectively. Although CelD has previously been 
considered to be more widespread in Caucasians, it is now increasingly being recognized in Asia, the 
Middle East and North Africa. In the North Indian state of Punjab, the prevalence of CelD in 4347 
school children aged 3-17 years was 0.3% (Sood et al. 2006). In a study performed in the UK, a higher 
incidence rate for UK-resident North Indians (6.9/100 000/year) was reported compared to 
Caucasians (2.5/100 000/year) living in the same area (Sher et al. 1993). Similar results have been 
reported in a study performed in Iran, which consisted of 2000 healthy blood donors representing 
the general population (Shahbazkhani et al. 2003). One person in every 166 individuals was 
predicted to have CelD. In a study carried out in two Egyptian pediatric cohorts, the prevalence of 
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CelD in one cohort (1500 children, seven months- 18 years) was 0.53% (Abu-Zekry et al. 2008). The 
prevalence of CelD in the other group, (150 children, six months- 13 years) admitted for diarrhea or 
failure to thrive, was 4.7%. In 250 children and adolescents with type-1 diabetes (T1D), the CelD 
prevalence was reported to be 6.4%. In North Africa, a CelD prevalence of 5.6% has been reported in 
Saharawi children (Catassi et al. 1999). There are reports suggesting that females are diagnosed two 
to three times more frequently compared to their male counterparts (Bai et al. 2005, Green et al. 
2001) and that males have more severe symptoms at presentation. These studies suggest that CelD 
is no longer a disease of the West, but one affecting an equivalent number of people in other parts 
of the World as well.  
CelD patients suffer from a wide spectrum of intestinal and extraintestinal symptoms which severely 
affects their quality of life. Both genetic predisposition and environmental factors are necessary for 
disease onset. Although gluten is the ultimate trigger for CelD onset, other environmental factors 
such as the duration of breast-feeding in childhood, timing of gluten introduction in an infant’s diet 
and amount of gluten when introduced as well as the composition of gut microbiota have been 
proposed to affect CelD risk (Ludvigsson, Fasano 2012). An increased risk for CelD has also been 
associated with childhood infections with Adenovirus 12 and Hepatitis C virus (Plot, Amital 2009). 
However, Myleus et al. reported that repeated infections, of any type, in the first six months of life 
significantly increased the risk for CelD in later life (Myleus et al. 2012). In strong contrast to this, it 
has also been suggested that early infections may have a protective role in CelD (Plot et al. 2009), 
which is in agreement with the hygiene hypothesis in autoimmune diseases (Rook 2012). According 
to the hygiene hypothesis, increased cleanliness in developed countries has resulted in diminished 
interaction between microbes and humans. This has had a negative impact on the development of 
an immune system tolerant to innocuous environmental antigens. To date, a life-long GFD remains 
the only treatment for CelD.  
2.2. Clinical features 
CelD was long considered a disease of the childhood characterized by malabsorption and 
steatorrhea (Andersen 1947). It is now clear that it can affect genetically susceptible individuals at 
any age. CelD patients suffer from a wide range of intestinal and/or extraintestinal symptoms. An 
individual may present with symptoms indicative of classical or non-classical CelD. Classical CelD is 
considered to arise in early infancy and is characterized by villous atrophy and crypt cell hyperplasia 
(Figure 1). The typical symptoms of classical CelD include diarrhea, steatorrhea, poor appetite, 
failure to thrive, muscle wasting, malnutrition and abdominal distension and pain (Young, Pringle 
1971, D'Amico et al. 2005). Non-classical CelD is more prevalent among older children and adults.  
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Figure 1. The characteristic features of classical CelD are shown. Photographs courtesy of Juha Taavela. 
These patients have a few or no intestinal symptoms reminiscent of classical CelD. Symptoms 
associated with non-classical CelD often include recurrent abdominal pain, nausea, vomiting, 
bloating, dental enamel defects and recurrent aphthous stomatitis (Bucci et al. 2006). These patients 
may also present with extraintestinal symptoms such as arthritis, neurological symptoms and 
anemia or the disease may be silent without any apparent symptoms (Ludvigsson et al. 2004, 
Branski, Troncone 1998).  Such diverse symptoms sometimes lead to a delay in diagnosis. 
Undiagnosed and newly diagnosed CelD patients may suffer from anemia, which may be a result of 
poor iron absorption, folate deficiency or vitamin B12 deficiency (Tikkakoski, Savilahti & Kolho 2007, 
Halfdanarson, Litzow & Murray 2007). These patients recover from anemia by following GFD in 
conjunction with iron supplements. Less than 5% of CelD patients develop refractory celiac disease 
(RCD). Such patients experience persistent symptoms, severe villous atrophy, do not respond to a 
GFD and may develop other complications later (Verbeek et al. 2008).  
2.3. Genetics of celiac disease 
The genetic architecture of an individual is just as important for CelD development as the disease 
triggering environmental factor, gluten. Genetic variants within the HLA locus on chromosome six 
are associated with increased risk for CelD (Sollid et al. 1989). The primary risk for developing CelD is 
associated with the HLA-DQ2 heterodimer which is composed of the protein products of the HLA-
DQA1*0501 and HLA-DQB1*0201 alleles (Sollid et al. 1989). This heterodimer is present in about 
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95% of CelD patients of European descent. The alpha- and beta chains of the DQ2 heterodimer can 
be encoded in cis (i.e. both on the same DRB1*03 (DR3) haplotype, also called the DQ2.5 haplotype) 
or in trans (i.e. with the DQA1*05 allele on DRB1*11, DRB1*12 or DRB1*13 haplotype and the 
DQB1*02 allele on DRB1*07 (DR7) haplotype) configuration (Spurkland et al. 1992, Mazzilli et al. 
1992). The remaining 5% of CelD patients carry the HLA-DQ8 heterodimer (Spurkland et al. 1992). 
The DQ8 heterodimer is composed of proteins encoded by the HLA-DQA1*03 and DQB1*0302 
alleles. The HLA-DQ2 and –DQ8 encoding genotypes are quite common (20%-30%) in the general 
population in Western countries (Sollid et al. 1989, Polvi et al. 1996, Cummins, Roberts-Thomson 
2009). They have also been reported to occur at a relatively high frequency in Northern and Western 
Africa, the Middle East and Central Asia (Cummins, Roberts-Thomson 2009). In contrast, the HLA-
DQ8 encoding genotypes have a worldwide distribution, whereas DQ2.5 is quite common in South 
and Central America and DQ8 is present in about 90% of Amerindian populations (Gujral, Freeman & 
Thomson 2012).  
The concept of HLA-DQ2 gene dose effect in CelD is well established (Karinen et al. 2006, Congia et 
al. 1994). Vader and colleagues demonstrated that HLA-DQ2.5 homozygous individuals have the 
highest risk for CelD development followed by HLA-DQ2.2/2.5 heterozygous individuals (Vader et al. 
2003). The HLA-DQ2 or -DQ8 heterodimers are required but not sufficient for CelD development 
suggesting the existence of other non-HLA disease predisposing genes. Further insight into the 
contribution of HLA- and non-HLA genes in CelD is provided by studies comprising monozygotic and 
dizygotic twin-pairs. The concordance rate between monozygotic twins is significantly higher (up to 
75%) than in dizygotic twins (up to 11%) (Greco et al. 2002, Nistico et al. 2006). The concordance 
rate between monozygotic twins and HLA identical sibs is estimated to be 70% and 30% respectively 
and the risk contribution of the MHC region is suggested to be no more than 40% (Houlston, Ford 
1996, Bevan et al. 1999). Genetic studies have been performed to identify non-HLA genes which 
confer risk for CelD development. 
2.3.1. Linkage studies in celiac disease 
Linkage studies are performed in families with at least two affected individuals, usually siblings, and 
the segregation of specific genetic markers (microsatellites or single-nucleotide polymorphisms 
(SNPs)) is followed within the family. SNPs are distributed over the whole genome and inherited by 
offspring from parents. The idea behind following certain SNPs in genome-wide linkage scans to 
identify disease associated risk genes is that SNPs and haplotypes close to a disease causing gene are 
likely to be inherited identically by the affected siblings or other relatives. As compared to free 
inheritance, the loci with an excess of sharing between relatives in all the tested families show 
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genetic linkage to the disease.  Linkage studies have been used to study small genomic region 
harboring potentially interesting genes or at a genome-wide level. In candidate gene studies, there is 
some evidence or indication for the involvement of the gene in disease susceptibility. This approach 
has led to the identification of several risk loci which have been independently replicated in different 
populations. Multiple studies have reported linkage to 2q33 (CELIAC3) (Holopainen et al. 1999, 
Naluai et al. 2000, Popat et al. 2002b, Holopainen et al. 2004). Some studies have reported linkage 
to 5q31-33 (CELIAC2) (Koskinen et al. 2009b) and 19p13 (CELIAC4) (Koskinen et al. 2008, Van Belzen 
et al. 2003). However, in a study by Seegers et al., no evidence of linkage to CELIAC2 region was 
found in a Dutch cohort (Seegers et al. 2003). The 2q33 region harbors genes like CTLA4, ICOS and 
CD28, which have roles in T-cell mediated immunity and the MYO9B gene, located in the 19p13 
chromosomal region, may be involved in the regulation of actin cytoskeleton or tight junctions. In 
contrast to the candidate gene studies, genome-wide studies are assumption free. A few 
chromosomal regions have been repeatedly highlighted in different genome-wide linkage scans, e.g. 
5q31-33 (Greco et al. 1998, Naluai et al. 2001), 2q33 (King et al. 2000, Naluai et al. 2001), and 19p13 
(Van Belzen et al. 2003, Popat et al. 2002a, van Belzen et al. 2004). These studies have been 
summarized in Table 1. The linkage approach has been quite successful in monogenic Mendelian 
diseases. However, results in polygenic complex diseases have been less fruitful as linkage scans in 
different populations have been somewhat contradictory. 
Table 1. Linkage studies performed in celiac disease 
Locus/Chromosome Candidate gene linkage studies Genome-wide linkage studies 
CELIAC2/5q31-33 (Koskinen et al. 2009b, Seegers et al. 
2003) 
(Greco et al. 1998, Naluai et al. 
2001) 
CELIAC3/2q33 (Holopainen et al. 1999, Naluai et al. 
2000, Popat et al. 2002b, Holopainen et 
al. 2004) 
(King et al. 2000, Naluai et al. 
2001) 
CELIAC4/19p13 (Koskinen et al. 2008, Van Belzen et al. 
2003) 
(Van Belzen et al. 2003, Popat 
et al. 2002a, van Belzen et al. 
2004) 
 
2.3.2. Association studies in celiac disease 
In contrast to family-based linkage studies, association studies are performed on a group of 
unrelated disease affected individuals (referred to as cases) and healthy individuals (referred to as 
controls). This method compares allele frequency (or genotype distribution), in one or more SNPs (or 
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other genetic polymorphisms) at a given locus in the genome, between cases and controls. A SNP is 
said to be associated with a disease if a significant difference in allele frequency (or genotype 
distribution) is observed between cases and controls. Alleles that exist close to each other at a given 
genetic locus tend to be inherited together more often than is expected by chance. Such alleles are 
said to be in linkage disequilibrium (LD). SNPs (or other polymorphisms) that are in LD share 
common ancestry because they have not been separated by mutations or recombination events 
across generations (Gabriel et al. 2002). The strength of LD between two markers is assessed by D’ 
or r2. A D’ or r2 value equal to zero means that the markers are independent and a value equal to 
one means that the two markers coexist. If the rarer allele always occurs with one of the two alleles 
at the other marker, D’ is equal to one. In contrast, r2 is equal to one if the allele frequencies 
between the two SNPs are identical. Thus, if two or more SNPs are in LD, it is enough to genotype 
one of these SNPs as it provides information on genetic variants at other loci in the LD group. In 
association studies, this method greatly reduces the number of SNPs required to be genotyped to 
cover common genetic variants at a given locus.    
The CELIAC3 locus identified in linkage scans was independently validated by association studies 
(Holopainen et al. 1999, Djilali-Saiah et al. 1998, Hunt et al. 2005). The association of SNPs in the 
CELIAC2 and CELIAC4 loci has been reported in some studies (Koskinen et al. 2009b, Van Belzen et al. 
2003, Monsuur et al. 2005) but not in others (Koskinen et al. 2008, Giordano et al. 2006, Hunt et al. 
2006, Ryan et al. 2005). The association approach to candidate gene studies has identified several 
other genomic regions harboring genes, among others intracellular adhesion molecule-1 (ICAM-
1)(Abel et al. 2006), immunoglobulin G Fc receptor 2a (FcgR2a) (Alizadeh et al. 2007), IL-10 (Barisani 
et al. 2006) and IL23R (Nunez et al. 2008). Nevertheless, other studies have reported a lack of 
association between polymorphisms within the ICAM-1 (Dema et al. 2008) and IL23R genes 
(Weersma et al. 2008, Einarsdottir et al. 2009). A summary of the studies described here is given in 
Table 2. 
In the first CelD genome-wide association study (GWAS) (Table 2), the association of 310,605 SNPs 
was tested in 778 CelD patients and 1,422 healthy individuals (van Heel et al. 2007). In addition to 
the HLA locus, this study identified a genomic region on chromosome four encompassing the 
KIAA1109-TENR-IL2-IL21 genes. This finding was further validated in Dutch and Irish cohorts. Of the 
four genes in this region, the genes IL2 and IL21 are particularly interesting. The IL2 cytokine can 
stimulate T-cell activation and proliferation in an autocrine manner and IL21 enhances B cell, T cell 
and NK cell proliferation and IFN-γ production. The GWAS by van Heel et al. was a landmark study 
which set the stage for other GWAS performed in different populations.  One thousand twenty of 
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the most strongly associated SNPs in the GWAS by van Heel et al. (van Heel et al. 2007) were studied 
in a follow up association study (Hunt et al. 2008). This study consisted of independent CelD cases 
and healthy control subjects (cases: 1643, controls: 3406) from the UK, Ireland and the Netherlands. 
Twenty-one non-HLA SNPs from eight different chromosomal locations (1q31, 2q11-2q12, 3p21, 
3q25-3q26, 3q28, 6q25 and 12q24) meeting a genome-wide statistical significance (P overall < 5 x 10-
7) were reported in this study. Six of the loci identified harbor genes (1q31: regulator of G-protein 
signaling 1, RGS1; 2q11-2q12: interleukin-18 receptor accessory protein, IL18RAP; 3p21: chemokine 
receptor 3, CCR3; 3q25-3q26: interleukin-12A, IL12A; 6q25: T-cell activation GTPase activating 
protein, TAGAP and 12q24: SH2B adapter protein 3, SH2B3) which are involved in the regulation of 
immune responses. A marker (rs1464510) at 3q28 locus on chromosome three, containing the lim 
domain-containing preferred translocation partner in lipoma (LPP) gene was also associated with 
CelD. Although LPP is expressed at high levels in the small intestine, its function in CelD pathogenesis 
is not entirely clear. Findings from the first CelD GWAS and the follow-up association study by Hunt 
et al. (van Heel et al. 2007, Hunt et al. 2008) were followed up in an Italian cohort comprising 538 
CelD patients and 593 healthy controls (Romanos et al. 2009). Six of the eight new CelD loci were 
replicated in this study and, interestingly, two loci (3p21-CCR3; 2q11-2q12-IL18RAP) showed no 
association with CelD in the Italian population. In contrast, another study confirmed the association 
of IL18RAP locus with CelD in a Hungarian cohort (cases: 607, controls: 448), but not in Finnish 
(cases: 844, controls: 698) or Italian (cases: 187, controls: 239) cohorts (Koskinen et al. 2009a). 
Results from these studies point towards the presence of population-specific differences in 
susceptibility genes. Trynka et al. studied the association of 458 SNPs that were only modestly 
associated with CelD in the GWAS by van Heel et al.(van Heel et al. 2007, Trynka et al. 2009) This 
study included samples from four different Caucasian populations (total cases: 2987, total controls: 
5273) and identified two new (6q23.2-OLIG3, TNFAIP3 and 2p16.1-REL) risk loci. The protein 
products of TNFAIP3 and REL are involved in the regulation of the nuclear factor kappa-B (NFkB) 
pathway which plays a critical role in promoting immune and inflammatory responses. CelD is a 
complex disease and several genes with small effect size may also play a role in its predisposition. 
Discovering such genes requires large sample sizes.  
A second GWAS was carried out in five European CelD case and control sample collections (total 
cases: 9,451 and total controls: 16,434) (Dubois et al. 2010). Such a study may not be able to identify 
population-specific risk loci due to genetic heterogeneity of the samples, but is likely to discover 
common risk genes with relatively low effect size. This GWAS identified several non-HLA genes with 
known functions in immune system regulation (Dubois et al. 2010). In addition to confirming 
association [with genome-wide significant evidence (P < 5 x 10-8)] with 13 previously identified non-
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HLA CelD risk loci (RGS1, REL, IL18RAP, ITGA, CTLA-4/ICOS/CD28, CCR1, CCR 3, CCR5, CCR9, IL-12A, 
LPP, IL-2/ IL-21, TNFAIP3, TAGAP, SH2B3 and PTPN2), association with thirteen new loci (TNFRSF14, 
RUNX3, PLEK, CCR4, CD80, BACH2, THEMIS, ZMIZ1, ETS1, CIITA, CLEC16A and ICOSLG) was reported. 
Furthermore, another 13 loci (PARK7/TNFRSF9, NFIA, CD247, FASLG, TNFSF18, FRMD4B, IRF4, 
ELMO1, ZFP36L1, UBEEL3, TLR7/TLR8) were suggested to be associated with CelD. Although this 
study brought the number of confirmed CelD non-HLA risk loci to 26, these loci only explain a 
fraction of the disease heritability and most of the common and rare risk variants remained 
unknown. The immunochip consortium (Cortes, Brown 2011) was developed to identify additional 
rare and common risk variants and causal genetic polymorphisms in immunological diseases. In 
order to densely genotype loci associated with an immunological disease using the 1000 genomes 
project data (1000 Genomes Project Consortium et al. 2012) and other available disease-specific 
resequencing data, a custom Illumina Infinium High-Density array (called the immunochip) was 
developed. This consortium took into account that many risk loci are shared across different 
autoimmune or chronic immune-mediated diseases (Zhernakova et al. 2011, Coenen et al. 2009, 
Zhernakova, van Diemen & Wijmenga 2009, Zhernakova et al. 2007, Smyth et al. 2008). Thus, for the 
immunochip, the consortium selected 186 distinct loci containing genome-wide significant markers 
(P < 5 x 10-8) from 12 immune-mediated diseases (UC, CD, T1D, SLE, rheumatoid arthritis (RA), 
psoriasis, primary biliary cirrhosis, MS, IgA deficiency, CelD, ankylosing spondylitis and autoimmune 
thyroid disease). Using the immunochip,Trynka et al., densely genotyped 183 non-HLA risk loci in 
12 041 CelD patients and 12 228 healthy subjects and the association of 139 553 SNPs was studied 
(Trynka et al. 2011). SNPs at these loci have been reported previously to be associated with immune-
mediated diseases. This study identified 13 novel risk loci (FASLG, STAT4, IRF4, PTPRK, EMLO1, 
PFKFB3/PRKCQ, POU2AF1/C11orf93, TREH/DDX6, ZFP36L1, CLK3/CSK, CIITA, UBASH3A, UBE2L3/YDJC 
and HCFC1/TMEM187/IRAK) taking the total number of CelD susceptibility loci to 40. The presence 
of certain variants within these regions inappropriately affect the innate and adaptive immune 
responses to gluten peptides ensued by a persistent intestinal inflammation. Inarguably, the 
immune system has a central role in disease progression and identifying factors that modulate the 
immune system is a key step in solving the CelD puzzle. 
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Table 2. Association studies performed in celiac disease. 
Loci/Genes identified or investigated References 
CELIAC2 (5q31-q33) (Koskinen et al. 2009b, Ryan et al. 2005) 
CELIAC3 (2q33) 
(Holopainen et al. 1999, Djilali-Saiah et al. 
1998, Hunt et al. 2005) 
CELIAC4/MYO9B (19p13) 
(Van Belzen et al. 2003, Monsuur et al. 
2005)(Koskinen et al. 2008, Giordano et al. 
2006, Hunt et al. 2006) 
ICAM-1 (19p13.2) (Abel et al. 2006, Dema et al. 2008) 
FcgR2a (1q23.3) (Alizadeh et al. 2007) 
IL-10 (1q32.1) (Barisani et al. 2006) 
IL23R (1p31.3) 
(Nunez et al. 2008, Weersma et al. 2008, 
Einarsdottir et al. 2009) 
KIAA1109-TENR-IL2-IL21 (4q27) (van Heel et al. 2007) 
RGS1(1q31), IL18RAP (2q11-q12), CCR3 (3p21), 
IL12A (3q25-q26), TAGAP (6q25), SH2B3 
(12q24) 
(Hunt et al. 2008, Koskinen et al. 2009a, Dema 
et al. 2009) 
IL2-IL21 (4q27), RGS1 (1q31), IL12A/SCHIP1 
(3q25-q26), LPP (3q28), SH2B3/ATNX2 (12q24), 
TAGAP (6q25) (Romanos et al. 2009) 
OLIG3-TNFAIP3 (6q23.3), REL (2p16.1) (Trynka et al. 2009) 
TNFRSF14 (1p36.32), RUNX3 (1p36.11), PLEK 
(2p14-p13), CCR4 (3p22.3), CD80 (3q13.33), 
BACH2-MAP3K7 (6q15), PTPRK-THEMIS 
(6q22.33), ZMIZ1 (10q22.3), ETS1 (11q24.3), 
CIITA-SOCS1-CLEC16A (16p13.13), ICOSLG 
(21q22.3) (Dubois et al. 2010) 
FASLG (1q24.3), STAT4 (2q32.2-q32.3), IRF4 
(6p25.3), PTPRK (6q22.33), EMLO1 (7p14.2-
p14.1), PFKFB3/PRKCQ (10p15.1), POU2AF1 
(11q23.1), TREH/DDX6 (11q23.3), ZFP36L1 
(14q24.1), CLK3/CSK (15q24.1), CIITA 
(16p13.13), UBASH3A (21q22.3), UBE2L3/YDJC 
(22q11.2-q13.1) and HCFC1/TMEM187/IRAK 
(Xq28) (Trynka et al. 2011) 
underlined: no evidence for association 
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2.4. Celiac disease pathogenesis- the role of innate and adaptive immunity 
Already in the 1940s, the Dutch pediatrician Willem-Karel Dicke realized that there was something in 
wheat that was responsible for causing CelD (van Berge-Henegouwen, Mulder 1993) but only 
decades later gliadin peptides were implicated as the main disease trigger (Figure 2). Gluten is a 
storage protein present in food grains such as wheat, rye and barley. It comprises alcohol-soluble 
gliadins and alcohol-insoluble glutenins. In the stomach and small intestine, the proteolytic enzymes 
pepsin and trypsin, respectively, act upon these proteins. The high content of glutamine and proline 
in gliadin makes it highly resistant to degradation by proteolytic enzymes (Shan et al. 2002, Shan et 
al. 2005). Although these peptides evoke both the innate and adaptive immune systems, it is the 
onset of mucosal adaptive immunity to certain gliadin peptides (immunodominant peptides e.g. p57-
68) which is detrimental in CelD. There are also cytotoxic gliadin peptides (p31-43 or p31-49) which 
trigger the innate immune system (Maiuri et al. 2003a) and induce enterocyte apoptosis (Maiuri et 
al. 2003a, Giovannini et al. 2003) and proliferation (Barone et al. 2011).  
Moss et al. reported an increased rate of apoptosis in biopsy samples from untreated CelD patients 
compared to that seen in controls (Moss et al. 1996).  Similarly, a significant increase in the number 
of proliferating cells in the crypts was observed in biopsies from active CelD patients. Both, apoptosis 
and proliferation rate decreased in these patients upon gluten withdrawal from diet demonstrating 
their gluten dependence. The involvement of the Fas-FasL pathway has been investigated using CelD 
biopsy samples. Maiuri et al. showed that in vitro gliadin challenge of biopsy samples from untreated 
CelD patients induces apoptosis via a Fas-dependent pathway (Maiuri et al. 2001) and IELs of more 
than 50% of untreated CelD patients express FasL. A coculture experiment using enterocytes and 
lamina propria mononuclear cells (LPMNCs) isolated from untreated CelD patients was performed 
(Ciccocioppo et al. 2001). It was shown that FasL expressing LPMNCs selectively target Fas expressing 
enterocytes and induce apoptosis. In the lamina propria, gliadin peptides (in particular the p31-43 
peptide) induce the expression and secretion of interleukin-15 (IL-15) in lamina propria mononuclear 
cells (LPMNCs) and the expression of proliferation marker Ki67, FAS and TFR on epithelial cells 
(Maiuri et al. 2003a, Maiuri et al. 2000). Similar effects were reported for biopsy samples exposed to 
IL-15. Enterocyte apoptosis induced by gliadin and IL-15 could be abolished by anti-IL-15 antibodies. 
Recently, it was shown that IECs also produce increased levels of IL-15 after exposure to gliadin 
peptides (Barone et al. 2011). Interleukin-15 produced by dendritic cells and macrophages induces 
strong surface expression of MICA (Hue et al. 2004) a receptor for NKG2D expressed by cytotoxic 
CD8 αβ- and  γδ-T cells. An interaction between MICA and NKG2D induces enterocyte apoptosis by 
intraepithelial lymphocytes (IELs) which results in extensive mucosal damage and the continued 
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introduction of gliadin peptides into the mucosa. Furthermore, IL-15 promotes the production of 
IFNγ by IELs (Di Sabatino et al. 2006, Garrote et al. 2008). Interleukin 15 may also act in an autocrine 
manner as it has been shown to induce anti-apoptotic pathways in IELs (Malamut et al. 2010).  
In response to gliadin exposure, intestinal epithelial cells (IECs) have been shown to release zonulin 
(later identified as prehaptoglobin-2) in the cell medium (Drago et al. 2006, Tripathi et al. 2009). 
Zonulins binding to the cell surface are suggested to induce changes in cell cytoskeleton and increase 
monolayer permeability presenting a paracellular route into the mucosa.  Apical to basal 
retrotranscytosis of gliadin peptides mediated by the transferrin receptor (TFR) CD71 and facilitated 
by secretory IgA (sIgA) antibodies has been proposed (Matysiak-Budnik et al. 2008, Heyman, Menard 
2009). Apoptosis of enterocytes by gliadin peptides and direct sampling of gluten peptides in 
intestinal lumen by dendritic cells (DCs) are other proposed mechanisms (Chieppa et al. 2006, 
Rescigno et al. 2001). The transcellular pathway for gliadin transport has been associated with 
enterocyte proliferation and oxidative stress. In epithelial cells, the gliadin peptides are endocytosed 
which delays the maturation of early endosomes into late endosomes (Barone et al. 2010). These 
peptides were also shown to prolong the activation of the epidermal growth factor receptor (EGFR) 
pathway, which was implicated in the proliferation of epithelial cells (Barone et al. 2007b). It was 
recently shown that overnight stimulation of Caco-2 cells with gliadin peptides increases IL-15 gene 
transcription, which is dependent on preexisting IL-15 (Barone et al. 2011). Interestingly, the gliadin 
induced proliferation was found to be dependent on IL-15 and EGFR pathways. In other studies, 
effects like the disruption of epithelial tight junctions (TJs) (Ciccocioppo et al. 2006, Sander et al. 
2005), cellular oxidative and endoplasmic reticulum (ER) stress (Luciani et al. 2009, Caputo et al. 
2012) and alterations in actin cytoskeleton and protein trafficking (Reinke et al. 2011) have been 
reported in epithelial cells which are exposed to pepsin and trypsin digested gliadin (PT-G). It is, 
however, not certain which of these mechanisms is the primary method for gliadin translocation 
across intestinal epithelial layer. It is possible that gliadin peptides enter the mucosa through several 
different mechanisms and many are still unknown. 
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Figure 2. The innate and adaptive immune responses in celiac disease. sIgA: secretory immunoglobulin A class antibodies, 
CD71: transferrin receptor, p31-43 and p57-68: gliadin derived peptides corresponding to the amino acids 31-43 and 57-68, 
respectively. INFγ: interferon gamma, IL-15: interleukin-15, NK cell: natural killer cell, tTG: tissue transglutaminase; Q: 
glutamine, E: glutamate, IEL: intraepithelial lymphocyte, DC: dendritic cell. 
Tissue transglutaminase (tTG) or transglutaminase 2 (TG2) belongs to a family of calcium-dependent 
enzymes that catalyze the crosslinking of proteins and participates in wound healing process. tTG is 
normally present in the cytoplasm but can also be released during an injury. It’s role as an 
autoantigen in CelD and gliadin as its preferred substrate was first described by Dieterich et al. 
(Dieterich et al. 1997). Both, CelD associated HLA-DQ2 and –DQ8 molecules (expressed by APCs) 
have a preference for binding peptides that have negatively charged residues at certain positions 
(Vartdal et al. 1996, Godkin et al. 1997). It was subsequently shown that tTG selectively deamidates 
glutamine residues in gliadin to negatively charged glutamic acid (also known as glutamate) (van de 
Wal et al. 1998), thus highly improving its affinity for DQ2 and DQ8 molecules on APCs. The adaptive 
T-cell response to gluten in CelD is mainly driven by CD4+ T (Th1) cells. The cells have a cytokine 
profile of Th1 cells (Nilsen et al. 1995, Nilsen et al. 1998), which is dominated by IFNγ. Tregs are also 
present in the intestine and play an important role in the induction of tolerance to self-antigens and 
dietary proteins (Gianfrani et al. 2006). However, several studies report impairment in the function 
of Treg cells (Granzotto et al. 2009, Hmida et al. 2012) in CelD. Following the discovery of Th17 cells 
and their involvement in the pathogenesis of other autoimmune diseases, it was speculated that 
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Th17 cells may also be responsible for driving mucosal inflammation in CelD. This idea was 
particularly interesting as an impairment of Treg cell function had been reported. Results from studies 
on Th17 cells in CelD have been rather contradictory. Monteleone et al. found higher expression of 
IL-17A RNA and protein in active CelD biopsy samples compared to inactive CelD and normal 
mucosal biopsy samples (Monteleone et al. 2010). The authors suggested that in active CelD 
patients, IL-17A was mainly produced by CD4+ T cells and double positive CD4-CD8+ T cells. Similarly, 
Castellanon-Rubio et al. found signatures of both Th1 and Th17 CD4+ T cells in active CelD 
(Castellanos-Rubio et al. 2009). In contrast to these studies, Bodd et al. reported that gluten-specific 
T cells produce IFNγ and IL-21 but not IL-17 or IL-22 (Bodd et al. 2010). Thus, the role of Th17 cells in 
CelD is elusive. Nonetheless IL-21 may have a bigger role than hitherto anticipated as it targets, 
among others, CD8+ T cells, NK cells and is important for B cell differentiation and plasma cell 
function.  
An autoimmune reaction to a self-protein, i.e. tissue transglutaminase (tTG), is mounted in CelD 
individuals. Immunoglobulin-A anti-gliadin antibodies (AGA) (Unsworth et al. 1981), IgA antibodies 
targeting connective tissue fibers, i.e. anti-reticulin antibodies (ARA) (Lerner, Kumar & Iancu 1994) 
and those targeting structures surrounding smooth muscle fibers, i.e. anti-endomysium 
autoantibodies (EMA) (Burgin-Wolff et al. 1991) and IgA (also IgG) anti-tissue transglutaminase 
antibodies (ATGA) are produced by plasma cells in the mucosa of CelD patients (Figure 2). In the 
small intestinal mucosa of CelD patients, these autoantibodies are found as IgA deposits below the 
basement membrane along the villous and crypt epithelium and around the blood vessels 
(Korponay-Szabo et al. 2004, Tosco et al. 2008). In active CelD, celiac-specific IgA antibodies are also 
found in the serum.  Interestingly, these autoantibodies are gluten dependent and disappear from 
the system upon gluten withdrawal in the diet (Sulkanen et al. 1998). With the identification of tTG 
as the CelD autoantigen (Dieterich et al. 1997) it soon became clear that both, EMA and ARA, target 
tTG (Korponay-Szabo et al. 2000). The mechanism of production and significance of autoantibodies 
against tTG in CelD pathogenesis are not clear. It is conceivable that tTG-specific B cells endocytose 
tTG-gliadin complexes and process them intracellularly (Sollid et al. 1997). The resulting gluten 
peptides are then presented to gluten-specific CD4+ T cells which activate B cells to produce 
antibodies against tTG. The tTG autoantibodies have been shown to promote epithelial cell 
proliferation (Barone et al. 2007a) and inhibit differentiation (Halttunen, Maki 1999), facilitate the 
passage of gliadin peptides across the epithelial layer (Rauhavirta et al. 2011) and promote the 
maturation of dendritic cells and their ability to stimulate T cells in a concentration dependent 
manner (Dalleywater, Chau & Ghaemmaghami 2012).  
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2.5. Diagnosis and treatment 
In May 1989, the European Society of Pediatric Gastroenterology, Hepatology and Nutrition 
(ESPGHAN) organized a workshop on “Diagnostic criteria of celiac disease” in Budapest, Hungary. 
The outcome of that meeting was presented in 1990. The ESPGHAN proposed a revised protocol for 
CelD diagnosis (Walker-Smith et al. 1990). Following new findings in the field of CelD, the criteria for 
the diagnosis has been revised again after a period of 20 years (Husby et al. 2012). The new report 
concludes that the diagnosis of CelD depends on symptoms which are dependent on gluten, the 
levels of CelD-specific autoantibodies, the presence of HLA-DQ2 and/or HLA-DQ8 and changes in the 
duodenal biopsy characteristic of histological changes in CelD (i.e. villous atrophy and crypt 
hyperplasia). A clinical remission and relief from all symptoms on a strict GFD should suffice for 
diagnosis with CelD. In asymptomatic patients, however, a gluten challenge and multiple control 
biopsies may be required to ascertain CelD.  
The examination of a small intestinal biopsy for mucosal changes (villous atrophy and crypt cell 
hyperplasia) and intraepithelial lymphocyte counts (≥25 per 100 enterocytes) is still the gold 
standard for CelD diagnosis. It is recommended that serological tests should be performed before 
referring a patient for intestinal biopsy and commencement of a GFD (Walker, Murray 2011). The 
contemporary approach for CelD diagnosis is to check serum levels of IgA (or IgG where relevant) 
ATGA, EMA or antibodies against deamidated gliadin peptides (Gujral, Freeman & Thomson 2012, 
Niveloni et al. 2007). Due to low sensitivity and specificity, the AGAs are very rarely used in 
diagnosis. The EMA and ATGA, on the other hand, show high levels of specificity and sensitivity 
(Walker, Murray 2011, Rostom et al. 2005). Despite high sensitivity and specificity (>91% and 99% 
respectively), a low positive predictive value (29%) has been demonstrated for tTG autoantibodies 
by Hopper et al. (Hopper et al. 2008). In the same study, when IgA tTG testing was combined with 
IgA EMA serological test, the positive predictive value was found to be 71.7%. Thus, using a two-step 
approach is also recommended. Serology is likely to miss some cases as 10-20% of untreated CelD 
patients may remain negative for serum EMA (Dickey, Hughes & McMillan 2000b) and may also 
exhibit less prominent small bowel histology (Abrams et al. 2004). Patients may also be tested for 
HLA-DQ2 or DQ8 molecules as >97% of CelD patients carry these molecules (Walker, Murray 2011) 
but a positive test does not confirm CelD as genes encoding these molecules are quite common (25-
40%) in the Western populations. A negative test is, nonetheless, a strong negative predictor of 
CelD. It is recommended that in the presence of negative serology, if the clinician remains suspicious 
of CelD, a biopsy examination should be undertaken. It has also been shown that in EMA-negative 
patients, gluten-dependent mucosal IgA tTG deposits may be present (Salmi et al. 2006). The 
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mucosal IgA deposits, in the absence of villous atrophy, are a good indicator of forthcoming CelD 
(Salmi et al. 2006, Kaukinen et al. 2005). Moreover, mucosal IgA tTG deposits are also useful in the 
follow up of patients with regards to small bowel mucosal recovery as they disappear slowly on a 
GFD compared to serum IgA levels (Koskinen et al. 2010, Dickey, Hughes & McMillan 2000a). 
A strict GFD is currently the only treatment for CelD. A life-long adherence is undoubtedly a daunting 
undertaking. However, the challenges associated with a GFD are outnumbered by health benefits. A 
number of alternative therapies/approaches (such as modification of toxic gliadin peptides, 
prevention of toxic gliadin peptide absorption, gliadin deamidation blockade and development of 
vaccines among others) are currently being developed (Gujral, Freeman & Thomson 2012), including 
detoxification of gluten peptides (Stenman et al. 2009, Stenman et al. 2010) and methods to prevent 
their uptake in the intestine. 
2.6. Celiac disease and associated disorders 
Individuals suffering from CelD have an increased risk for developing other diseases, many of which 
are of autoimmune nature. Collin et al. investigated the incidence of various CelD associated 
diseases in a group of 335 CelD patients and 335 age and sex matched control subjects with 
gastrointestinal symptoms, other than CelD (Collin et al. 1994). They reported that compared to the 
control group, CelD patients had a higher incidence of endocrine disorders (4.3% vs. 11.9%), T1D 
(1.5% vs. 5.4%), connective tissue diseases (2.7% vs. 7.2%), Sjögren’s syndrome (0.3% vs. 3.3%) and 
autoimmune thyroid diseases (2.7% vs. 3.6%). Subsequently, in a reciprocal manner, increased CelD 
incidence has been reported in T1D patients (Bhadada et al. 2011, Arato et al. 2003). In a study by 
Book et al., ten out of 97 Down’s syndrom patients had CelD (Book et al. 2001). In a group of 140 
pediatric patients suffering from autoimmune liver disease, 23 patients also had CelD (Caprai et al. 
2008). In this study, all 23 CelD patients remitted when they were put on a GFD in combination with 
immunosuppressive therapy. However, 14 patients had a relapse because they discontinued the 
immunosuppressive therapy or resumed gluten containing diet. Recently, in a Swedish study 
comprising 29000 patients with biopsy-proven CelD, a three-fold higher risk for SLE in CelD patients 
compared to the general population was reported (Ludvigsson et al. 2012). Why CelD patients, or 
autoimmune disease-affected individuals in general, are more prone to developing other 
autoimmune diseases is not clear. An explanation may lie in the fact that HLA risk haplotypes and 
many other risk genes are shared among different immune-mediated diseases. It is possible that 
different combinations of genes may be responsible for different disease outcomes.  
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2.7. Extraintestinal manifestation of celiac disease- dermatitis herpetiformis 
Dermatitis herpetiformis (DH) is an itchy and blistering skin disease, which predominantly affects the 
exterior surfaces of elbows, knees, buttocks, back and scalp. DH is an extra-intestinal manifestation 
of CelD, which appears in about 25% of CelD patients who may or may not have gastrointestinal 
symptoms (Collin, Reunala 2003). Although it was first described in 1884 by Louis Duhring(Duhring 
1983), its association with CelD was reported in 1966.(Marks, Shuster & Watson 1966) It is rather 
common in individuals with Northern European ancestry and affects more men than women with a 
male-to-female ratio ranging from 1.5:1 to 2:1.(Gawkrodger et al. 1984, Smith et al. 1992) Although 
it is considered relatively uncommon, several cases have been reported in Asian countries (Ohata et 
al. 2012, Sawhney, Singh 2011, Singal, Bhattacharya & Baruah 2002, Zhang et al. 2012). Earlier 
studies have reported the prevalence of DH to range from 10.4 to 66 per 100 000 individuals and the 
incidence rate has ranged from 0.4 to 2.6 per 100 000 individuals per year.(Gawkrodger et al. 1984, 
Reunala, Lokki 1978, Moi 1984, Collin et al. 1997) However, a recent study reported an increased 
prevalence (75.3 per 100 000 individuals) and incidence (3.5 per 100 000 individuals) of DH in 
Finland (Salmi et al. 2011). The age at DH onset is typically 30-40 years but the disease can also 
appear in the childhood or in older ages.(Reunala 2001, Ermacora et al. 1986) In addition, the first 
degree relatives of affected individuals are at greater risk for developing CelD and/or DH. In a study 
by Hervonen et al. the overall risk in first degree relatives was estimated to be 15 times higher than 
in the general population with the siblings being the most disease prone group among them 
(Hervonen et al. 2002). High concordance rates have been reported among siblings and twin pairs, 
where both twins are affected with CelD and DH or with either of the two diseases (Hervonen et al. 
2000, Karell et al. 2002). 
Despite its extraintestinal mode of presentation, DH is strongly associated with the HLA class II 
region on chromosome six. Spurkland et al. conducted a study including 50 DH patients and 290 
healthy control individuals (Spurkland et al. 1997). They found that genes encoding the HLA-DQ2 
heterodimer were present in 86% of the patients and 25% of the controls and another 12% of the 
cases carried genes encoding the HLA-DQ8 heterodimer. Thus HLA-DQ2 or HLA-DQ8 positivity is a 
major genetic risk factor for DH in Caucasians. Genes encoding these heterodimers are present in 
other populations also, albeit at a lower frequency (Liu, Cheng 2007). Recently, 91 DH patients of 
Japanese descent were found to have HLA genotypes distinct from HLA-DQ2 and –DQ8 (Ohata et al. 
2012), implying that population-specific genetic risk factors are likely to exist. In addition to the 
strongly associated HLA region, rare genetic variants of TNF family of genes were found to be 
present at a higher frequency in DH patients than in healthy controls (Messer et al. 1994). 
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Furthermore, in a study comprising CelD patients with DH, linkage to the 11q and 5q chromosomal 
regions, which harbor potentially relevant candidate genes for immunological diseases, was 
suggested (Holopainen et al. 2001). Another study by Koskinen et al. also provides some evidence of 
DH linkage to the 19p13 chromosomal region (Koskinen et al. 2008). The 19p13 region harbors a 
myosin gene, Myosin IXB (Myo9B), which encodes a protein with actin remodeling properties and a 
potential role in the maintenance of intestinal barrier. Independent linkage to and association with 
CelD of this region has been shown previously (Van Belzen et al. 2003, Monsuur et al. 2005). 
2.7.1. Diagnosis and treatment of dermatitis herpetiformis 
DH diagnosis is made based on the presence of granular IgA deposits in the dermal papillae 
demonstrated by direct immunofluorescence (DIF) examination.(van der Meer 1969) However, the 
presence of AGA and ARA and EMA has also been demonstrated in DH patients (Vainio et al. 1985, 
Hallstrom, Reunala 1985, McCord, Hall 1994). In a study by Beutner et al., DH cases were found to 
have negative DIF findings for junctional IgA deposits in two biopsy specimens but positive for IgA 
EMA and ATGA (Beutner et al. 2000). The presence of ATGA and EMA in DH has been suggested by 
other studies as well (Kumar et al. 2001, Chorzelski et al. 1983, Volta et al. 1992). As the use of DIF 
and serum tests for EMA and ATGA in DH cases not detected by DIF alone, the use of both tests in 
parallel for DH screening has been suggested (Kumar et al. 2001). Nevertheless, the test for EMA is 
done using an indirect immunofluorescence (IIF) method on sections of monkey esophagus 
(Chorzelski et al. 1983) making it both time-consuming and subjective. A serum test for the detection 
of ATGA has also been proposed as an alternative to DIF for DH diagnosis (Desai, Krishnan & Hsu 
2005). ATGA are also found in CelD patients without DH, rendering this method less effective. As in 
CelD, tTG was thought to be the major autoantigen in DH. It was later shown that the epidermal 
transglutaminase (eTG) is the autoantigen in DH against which the IgA antibodies are directed (Sardy 
et al. 2002). This observation finds support in recent studies where IgA antibodies against eTG 
correlated more strongly with DH (treated or untreated) than with CelD (Rose et al. 2009, Borroni et 
al. 2012). The authors concluded that IgA antibodies against eTG are the most sensitive serological 
marker in DH. Furthermore, as in CelD, a GFD is the only effective treatment for DH and is 
recommended even in the absence of gastrointestinal symptoms (Collin, Reunala 2003). DH patients 
are often advised to complement GFD with dapsone, a drug frequently used to soothe the rash 
symptoms (Reunala 2001). Strict adherence to a GFD usually mitigates the GI symptoms within a few 
weeks, however relief from rash may take a few months (Collin, Reunala 2003). A good response to a 
GFD has been reported in both pediatric and adult DH (Ermacora et al. 1986, Garioch et al. 1994). 
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Although a GFD is highly effective in soothing gluten-triggered enteropathy, non- or partial-
compliance with a GFD may lead to the development of other diseases. 
2.7.2. Dermatitis herpetiformis and associated diseases 
A higher incidence of several immune-mediated or other malignancies among DH patients has been 
reported. Reunala et al. studied a cohort of 305 DH patients over a period of ten years and found 
that different diseases were associated with DH (Reunala, Collin 1997). They reported that 4.3% of 
the DH patients had developed autoimmune thyroid disease, 1% had T1D, 1.3% had SLE, 1% had 
Sjögren’s syndrome, 1.3% had sarcoidosis and 1.6% of the DH patients had developed vitiligo or 
alopecia areata. RA, UC, SLE and splenomegaly have also been reported to have a high incidence 
among DH patients (Davies, Marks & Nuki 1978, Kurano, Lum & Izumi 2010). In a study comprising 
50 DH patients, 26 were found to have thyroid abnormalities (Cunningham, Zone 1985) whereas 
Hervonen et al. reported an increased prevalence of T1D in DH patients (2.3%) and their first-degree 
relatives (3.0%) compared with controls (Hervonen et al. 2004). High incidences of dental-enamel 
defects and chronic gastritis have also been reported in DH patients (Alakoski et al. 2012, Aine, Maki 
& Reunala 1992). Perhaps the most studied of associated diseases with DH is the association 
between DH and lymphoma. A majority of the lymphomas have been classified as non-Hodgkin’s 
lymphoma, however enteropathy-associated T-cell lymphoma (EATL) and B-cell lymphoma have also 
been reported (Sigurgeirsson, Agnarsson & Lindelof 1994, Hervonen et al. 2005, Viljamaa et al. 
2006). A significantly higher risk for non-Hodgkin’s lymphoma (relative risk of 5.4) in male patients 
was reported in a study conducted on Swedish cancer patients with DH (Sigurgeirsson, Agnarsson & 
Lindelof 1994). Furthermore, a protective effect of GFD on the development of lymphoma in DH 
patients has been demonstrated. Multiple studies have shown that only those DH patients who did 
not comply with a GFD or had been on a GFD for a period of less than five years had developed 
malignancies (Viljamaa et al. 2006, Leonard et al. 1983, Lewis et al. 1996).  
3. Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is a remitting and relapsing chronic inflammation of the GI tract, 
precipitated by unknown environmental factors in individuals with a certain genetic background. The 
two major forms of IBD are the closely related inflammatory disorders Crohn’s disease (CD) and 
ulcerative colitis (UC). In about 10% of cases, it is not possible to differentiate between CD and UC 
and the term IBD unclassified (IBDU) may be used. In UC, the inflammation is mainly restricted to the 
colonic mucosa, whereas in CD it can affect any part of the GI tract. Both UC and CD share several 
characteristic features but can be distinguished from each other on the basis of predisposing genes, 
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environmental risk factors, clinical, endoscopic and histological features. These features are listed in 
Table 3.  UC and CD have been shown to share a number of susceptibility genes (Anderson et al. 
2011, Franke et al. 2010). A wealth of information is now available on various risk factors, genetic 
and environmental, but no cure is yet available. The condition usually worsens with time and many 
patients have to undergo surgical procedures and take immunosuppressive drugs.  
Table 3. Features to Differentiate UC from CD 
Ulcerative colitis Crohn's disease 
Clinical features 
   
Diarrhea with urgency, often small volumes but 
frequent 
Diarrhea (often) accompanied by abdominal pain 
and malnutrition 
Bloody diarrhea is predominant Stomatitis (inflammation of the mouth) 
  Perianal lesions 
    
Endoscopic and radiological   
    
Diffuse superficial colonic inflammation Discontinuous transmural asymmetric lesions 
Rectum is involved, inflammation may be patchy  Mainly involving ileum and right- side colon 
Shallow erosions and ulcers  Cobblestone appearance 
Spontaneous bleeding  Longitudinal ulcers, Aphtous ulceration 
  Deep fissures 
Histopathological    
    
Diffuse inflammation in mucosa or submucosa Granulomatous inflammation 
Crypt architecture distortion  
Fissures or apthous ulcers can be seen; often 
transmural inflammation 
 
3.1. Crohn’s disease (CD) 
CD is a systemic inflammatory disease with episodes of remission and relapse. It is predominantly a 
disease of the gut which may also have extraintestinal manifestations. CD can affect the entire GI 
tract, from mouth to anus. Typically, CD patients suffer from a discontinuous inflammation in various 
parts of the GI tract with the development of complications like strictures, abscesses and fistulas. CD 
patients are phenotyped according to the Montreal classification of IBD (Silverberg et al. 2005). This 
classification takes into account the age (A) of disease onset, location (L) of the disease and disease 
behaviour (B) as the predominant phenotypic elements. The age has been further divided into three 
subgroups (A1: < 16 years, A2: 17-40 years and A3: > 40 years). The location (L)-group comprises four 
subgroups (L1: ileal, L2: colonic, L3: ileocolonic and L4: upper GI tract). The L4 location acts as a 
modifier that can be added to L1-L3 when concomitant upper GI disease is present. The disease 
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behavior is defined as B1 (non-stricturing, non-penetrating), B2 (stricturing) and B3 (penetrating). In 
addition, the perianal disease modifier (p) is added when concomitant perianal disease is present. All 
these features are shown in Figure 3.  
CD is dynamic in nature as its behavior has been reported to change over time. In a population-
based study, 306 patients were diagnosed between the ages (A2 category) of 17 and 40 years and 
the proportion of patients with disease location in L1, L2, L3 and L4 was 45%, 32%, 19% and 4% 
respectively (Thia et al. 2010). Furthermore, 81%, 5% and 14% of the patients had a B1, B2 and B3 or 
B3p phenotype, respectively. Altogether 19% of these patients progressed to a more aggressive 
phenotype within 90 days after diagnosis and over half of the patients (51%) experienced an 
intestinal complication within 20 years after diagnosis. In another study, Louis et al. reported that, 
10 years after initial diagnosis, 45.9% of patients had a change in disease behavior (Louis et al. 2001). 
The most prominent change was from non-stricturing, non-penetrating phenotype to either 
stricturing (27.1%) or penetrating (29.4%) phenotype. While age at diagnosis had no impact on this, 
ileal CD was more often stricturing and colonic or ileocolonic CD was more often penetrating. 
Studies in different cohorts indicate that one year after diagnosis, 10-30% of CD patients experience 
disease aggravation, 15-25% have low activity and 55-65% are in remission. (Munkholm et al. 1995, 
Loftus, Schoenfeld & Sandborn 2002). On long-term, 13-20% of CD patients have a chronic active 
course of disease activity, while 67-73% have a chronic intermittent course. Only a small proportion 
(10-13%) of CD patients remains in remission for several years. In a study by Jess et al., increased 
mortality compared to the general population was reported in CD patients (Jess et al. 2002). The CD-
related mortality was particularly higher in women compared to men. 
3.2. Ulcerative colitis 
UC is a relapsing inflammatory disease which involves the rectum and colon and extends in a 
continuous retrograde mode. The inflammation is generally diffuse and superficial. Depending on 
the anatomic location of inflammation, patients can be referred to as having ulcerative proctitis 
(involvement limited to the rectum), left-sided colitis (involving the sigmoid colon with or without 
the descending colon) or extensive colitis (also known as pancolitis) (Silverberg et al. 2005). The 
typical features of UC are shown in Figure 4. In patients with pancolitis, the last few centimeters of 
the ileum can also be inflamed. Such a backwash ileitis remains superficial and does not show deep 
ulcerations, stricture or fistula. Clinically, disease activity is described as mild (up to four bloody 
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Figure 3. The phenotypes of CD according to the Montreal classification. Modified from Baumgart and Sandborn (2012) 
and reprinted with permission. 
stools daily and no systemic toxicity), moderate (four to six bloody stools daily and minimal toxicity), 
severe (more than six stools daily and signs of toxicity such as fever anemia, raised erythrocyte 
sedimentation rate) or fulminant (Carter et al. 2004, Kornbluth, Sachar & Practice Parameters 
Committee of the American College of Gastroenterology 2004). The patients with fulminant disease 
may have more than ten stools daily, continuous bleeding, toxicity, abdominal tenderness and 
distension. They may also require blood transfusion and colonic dilation is visible on abdominal plain 
films. The course of the disease changes over time. In a study by Langholz et al., comprising 1161 UC 
patients, 9.1% of the cases had fulminant UC, 70.7% had moderate to high disease activity and 
20.2% had low disease activity (Langholz et al. 1991). In 18% of the UC patients, the whole colon was 
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affected (pancolitis), 36% had left-sided colitis and 44% had UC proctitis. In another study comprising 
515 UC patients, evaluation of the disease spread over-time revealed that 39% had progressed to a 
more advanced stage (Langholz et al. 1996). Of these, 4% had developed extensive colitis and in 
35%, the inflammation had spread to involve substantial part of the large bowel. Patients with 
extensive colitis have higher a risk for colectomy than those with proctitis (Hoie et al. 2007b). 
Despite severe manifestations, UC patients do not have higher mortality rates than the general 
population (Hoie et al. 2007a).  
Figure 4. Typical features of UC are shown in the figure. 
3.3. Clinical features of IBD 
In general, symptoms in IBD depend upon the GI segment which is affected. The symptoms may be 
mild or severe during relapses or they may decrease or completely disappear while the patient is in 
remission (Bernstein et al. 2010). IBD patients may present with symptoms like diarrhea (stool may 
contain mucus or blood, nocturnal diarrhea or incontinence), constipation (can be the primary 
symptom of UC which is limited to rectum), pain or rectal bleeding with bowel movement, severe 
bowel movement urgency, tenesmus (straining to urinate or defecate, without the ability to do so), 
abdominal cramps and pain (in CD in the lower right quadrant or around the umbilicus; in moderate 
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to severe UC in the lower left quadrant) and nausea and vomiting (more common in CD than in UC). 
Other symptoms which are more often associated with CD than with UC are fever, loss of appetite, 
weight loss, fatigue, night sweats, growth retardation and primary amenorrhea. 
Pediatric IBD patients present with the same symptoms as adult IBD patients but tend to have more 
extensive disease than adults at diagnosis (Langholz et al. 1997). Similarly, CD patients less than five 
years of age tend to have significant large bowel involvement (Kelsen, Baldassano 2008). This group 
may have more significant diarrhea (91%) at presentation compared to older children and adults 
(65%). Other symptoms which are more common in young children with CD are growth failure, 
anorexia, malaise, jaundice, late-onset puberty and osteopenia/osteoporosis (Kim, Ferry 2004). A 
retrospective pediatric cohort study of CD, which included 566 boys and 423 girls (age at diagnosis 0- 
17 years), reported that female CD patients had overall more severe course of disease but boys were 
at a greater risk for growth failure (Gupta et al. 2007). 
Up to 25% of IBD patients suffer from extraintestinal manifestations (EIM) of IBD and include 
arthralgia (pain in joint), arthritis (acute or chronic inflammation of a joint), ankylosing spondylitis (a 
chronic inflammatory disease of the axial skeleton), pyoderma gangrenosum (a chronic skin disease 
characterized by large spreading ulcers), erythema nodosum (an inflammation of the fat cells under 
the skin), iritis (inflammation of the iris of the eye), uveitis (inflammation of the uvea) and episcleritis 
(inflammation of the episcleral tissue) (Bernstein et al. 2010). Osteoporosis, venous 
thromboembolism (a blood clot that forms within a vein), avascular necrosis (cellular death of bone 
components) and mood disorders such as anxiety and depression are increased in IBD compared to 
the general population. Many of these complications may exist concomitantly in IBD patients and 
some may run an independent course from the IBD. In a study comprising 1649 pediatric IBD 
patients (28% of the patients were diagnosed with IBD at age less than six years) six percent had at 
least one EIM before diagnosis of IBD (Jose et al. 2009). The prevalence of EIM among children 
diagnosed before the age of six years and among older children was 3% and 7%, respectively. 
Arthritis (26%) and aphthous stomatitis (21%) were the most common before IBD diagnosis, whereas 
arthritis (17%) and osteopenia/osteoporosis (15%) were the most common EIM after IBD diagnosis.  
Intestinal complications are common in IBD (Bernstein et al. 2010). Profuse bleeding (hemorrhage) 
from ulcers is more common in UC than in CD. However, massive bleeding in CD is more often seen 
from ileal ulceration than colitis. Bowel perforation and intra-abdominal abscesses (a localized 
collection of pus often accompanied by swelling and inflammation) may also occur in CD (Poritz, 
Koltun 2007). Strictures in CD are often inflammatory and possible to resolve with medical 
treatment, whereas colonic strictures in UC are presumed to be malignant until proven otherwise. 
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Fistulas and perianal disease are the hallmarks of CD and surgical intervention is required in cases 
which do not respond to vigorous medical treatment or where abscesses have developed. Toxic 
megacolon (Hokama et al. 2012, Strong 2010) is a rare life-threatening colitis which is more common 
in UC than in CD. A surgical intervention is necessary if this condition is not resolved by medication 
within 24 hours. 
3.4. Epidemiology of IBD 
Inflammatory bowel disease may affect an individual at any age, but it generally starts in young 
adulthood and differs in the age of onset for UC and CD. The peak age for UC onset is usually 30-40 
years, whereas for CD it is 20-30 years (Cosnes et al. 2011). However, in 15-25% of cases IBD appears 
before 20 years of age (Kim, Ferry 2004, Oliva-Hemker, Fiocchi 2002). Pediatric IBD accounts for 
about 7-20% of all IBD cases and a majority of the cases are diagnosed between ten and 14 years of 
age. However, a small proportion (4%) of pediatric IBD is diagnosed before the age of five. A study 
which covered 56.5% of Swedish pediatric population reported that the median age at diagnosis for 
UC, CD and IC was 12.2 years, 13 years and 11.2 years respectively and 7.5% of the children were 
five years of age or less (Lindberg et al. 2000). In a study by Turunen et al. on a Finnish pediatric 
cohort, the mean age at diagnosis for UC, CD and IBDU was found to be 10.9 ± 4.1 years, 11.9 ± 3.7 
years and 10.8 ± 4.8 years, respectively (Turunen et al. 2006). Fourteen percent of the children were 
reported to be less than six years of age at the time of diagnosis in this study. This seems to be the 
general picture in the onset of pediatric IBD as similar results have been reported in other parts of 
the world (Gupta et al. 2007, Treepongkaruna et al. 2006). The incidence of UC is higher in men, 
whereas that of CD is higher in women (Bernstein et al. 2006, Molodecky et al. 2012). However, 
several studies conducted in Asia and the Middle East report higher incidence of CD in the male 
population (Molodecky et al. 2012). In a recent report by the World Gastroenterology Organization, 
it was asserted that despite the higher CD prevalence among female pediatric patients, the CD 
incidence rates have been greater among males over the past few years (Bernstein et al. 2010). 
Thus, an equalization of sex distribution may occur.  
The incidence and prevalence of IBD has increased over time, with more cases per year being 
reported in Southern and Eastern Europe, Asia and in other developing countries which were 
previously regarded as low-incidence areas (Ng et al. 2013). In a recent systematic literature review, 
the incidence of UC (person-year per 100 000 individuals) in Europe, Asia and the Middle East and in 
North America was reported to be 24.3, 6.3 and 19.2 respectively (Molodecky et al. 2012). The 
corresponding values for CD were 12.7, 5.0 and 20.2 respectively. The prevalence of UC (person-year 
per 100 000 individuals) in Europe ranged from 4.9 to 505, from 4.9 to 168.3 in Asia and the Middle 
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East and from 37.5 to 248.6 in North America while the CD prevalence rates were 0.6-322, 0.88-67.9 
and 16.7-318.5 for Europe, Asia and the Middle East and North America, respectively. In Europe, the 
highest incidence rate for UC was reported in Iceland (24.3 per 100 000) and for CD in the United 
Kingdom (10.6 per 100 000) (Thompson et al. 1998). However, in a recent study by Jussila et al. for 
the study period 2000- 2007, the mean annual incidence of IBD, UC and CD (per 100 000) was 
reported to be 34, 24.8 and 9.2 respectively (Jussila et al. 2012).In North America, Canada has the 
highest incidence rates for UC and CD at 19.5 and 20.2 per 100 000 respectively (Bernstein et al. 
2006). The incidence of IBD has been higher in developed countries and has long been associated 
with a westernized lifestyle. In the Pacific, Australia and New Zealand are highly developed and 
industrialized nations, which also share genetic background with Europeans and North Americans. 
Not surprisingly, high IBD incidence rates have been reported at these places (Gearry et al. 2010, 
Wilson et al. 2010).  
A similar increase in the incidence and prevalence of IBD in children has been observed. In Sweden, 
an increase in the incidence of pediatric UC (per 100 000) was reported from 4.6 in 1984-1986 to 7.0 
in 1993 -1995 (Lindberg et al. 2000). No change in the incidence of CD and IBDU was however 
reported. In Finland, the pediatric IBD incidence has increased three-fold (from 5 to 15) from 1987 to 
2003 with UC being the most prevalent disease (Lehtinen et al. 2011). During the years 1996-2006, 
the annual incidence of pediatric UC per 100 000 increased from 1.8 to 4.9 in Northern California 
(Abramson et al. 2010). In contrast to high UC incidence rate observed in these studies, an increase 
in the incidence of CD in children (aged 0-19 years) from 3.4 per 100 000 in 1988-1990 to 5.9 per 
100 000 in 2006-2007 was reported in France (Chouraki et al. 2011). A similar trend has been 
reported from other studies in the United Kingdom (Cosgrove, Al-Atia & Jenkins 1996, Henderson et 
al. 2012). What affects the differential rise in the incidence of UC and CD in different regions is not 
clear, but both genetic and environmental factors are likely to be responsible for this trend.  
IBD is more prevalent in developed and industrialized countries compared to the developing 
countries. In developed countries an increased incidence of IBD has been reported in urban areas 
compared to rural areas (Ekbom et al. 1991, Soon et al. 2012). The increase in IBD incidence in urban 
areas may be linked to dietary habits as multiple studies demonstrate that high animal protein 
intake, high sugar consumption and fat-rich food are risk factors for IBD (Sakamoto et al. 2005, 
Russel et al. 1998a). A rise in the occurrence of IBD has been observed in countries, which have 
adopted a westernized lifestyle, including India, China, Iran and Korea (Zheng et al. 2010, Desai, 
Gupte 2005, Firouzi et al. 2006, Yang et al. 2008). The exact factors contributing to an elevated risk 
are not known but may include, among others, changes in diet, improved sanitation and hygiene 
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standards. Indeed, In Eastern European countries such as Hungary and Croatia, IBD incidence rates 
comparable to those in Northern Europe have been reported (Lakatos et al. 2011, Sincic et al. 2006). 
In contrast, epidemiological studies from Romania and Poland report continued low-incidence rates 
for IBD (Gheorghe et al. 2004, Wiercinska-Drapalo et al. 2005). Whether the difference in incidence 
rates among these countries is real or due to differential diagnostic criteria is unclear.  
It has been proposed that higher exposure to sunlight and consequently higher vitamin D levels may 
have a protective effect on IBD progression. A study performed on 175 000 female American nurses 
found that increasing latitude of residence was associated with higher risk for IBD (Khalili et al. 
2012). Although this may hold true for North America and Northern European countries, it does not 
hold true for India where sunlight is found in abundance for most part of the year (Molodecky et al. 
2012, Desai, Gupte 2005). Smoking is associated with increased risk for CD (Lindberg, Jarnerot & 
Huitfeldt 1992, Russel et al. 1998b) but with protection from UC (Odes et al. 2001, Higuchi et al. 
2012). Despite positive associations reported between smoking and CD, a lack of association 
between the two has also been reported (Carlens et al. 2010, Reif et al. 1995, Reif et al. 2000). In a 
study comprising 339 affected sibling pairs who have similar genetic susceptibility for IBD (Bridger et 
al. 2002), smoking was associated with CD development (OR: 3.55) but protected from UC (OR: 0.28) 
and in 23 disease-discordant siblings pairs, the smoker had CD and the non-smoker had UC. Among 
other risk factors for IBD are appendectomy, repeated use of antibiotics in the first year of life and 
the use of oral contraceptives (Lopez-Serrano et al. 2010, Andersson et al. 2003, Virta et al. 2012, 
Cornish et al. 2008). The mechanistic details of how these factors affect the risk for IBD have not 
been outlined yet. 
3.5. Genetics of IBD 
Chronic inflammation in IBD results in severe mucosal damage. Although a dysregulated immune 
system is responsible for the inflicted mucosal injuries, it is the genetic architecture of the affected 
individual that lies at the heart of IBD pathogenesis.  
3.5.1. Family studies in IBD 
Familial aggregation has been reported in IBD. In a study published in 1963, Kirsner et al. outlined 
several studies where multiple members within a family were suffering from UC (Kirsner, Spencer 
1963). The first report of familial UC was published already in 1934 where two brothers and a sister 
were concordant for UC. The authors of this study concluded that UC is more common in the 
families of probands with UC. Subsequently, Mayberry et al. reported that nine percent of CD 
patients had first-degree relative with CD or UC (Mayberry, Rhodes & Newcombe 1980). The risk of 
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siblings developing the disease was estimated to be 30-times greater than that of the general 
population. In another study, the prevalence of IBD among relatives was reported to be 7.9% and 
the other affected individual was more often a sibling (Monsen et al. 1987). The prevalence of UC 
was 15-times higher in relatives than in non-relatives and the prevalence of CD in first-degree 
relative of UC patients was almost 3.5-times higher than in non-relatives. One of the first population-
based studies was performed on 637 patients with CD or UC in Copenhagen, Denmark (Orholm et al. 
1991). The results from the study revealed that the first-degree relatives of CD patients had a ten-
fold risk for CD compared to the general population. Similarly, a first-degree relative of UC patient 
had an eight-fold risk for UC. Furthermore, for a relative of a CD patient to get UC and for a relative 
of a UC patient to get CD, the relative risk was four-fold and two-fold respectively compared to the 
relatives of non-IBD individuals. These observations suggested that both CD and UC are genetically 
related and the genetic factor may be stronger in CD than in UC. This was further demonstrated in a 
UK study by Satsangi et al. In this study, of 317 CD and 825 UC patients, 41 (13%) and 90 (12%) 
patients respectively had a positive family history (Satsangi et al. 1994). Although these numbers are 
comparable, in 6.6% of the CD cases, the affected family member was a sibling compared to 3.75% in 
the UC cases. This suggests that first-degree relatives of CD patients are at higher risk of IBD than 
that of UC patients. As reported by Peeters et al., 132 of 640 probands with CD had a positive IBD 
family history compared to only 17 (of total 797) control individuals (Peeters et al. 1996). In addition, 
the risk was particularly high (10.4% after age adjustment) for the offspring of a CD affected 
individual and daughters were at higher risk (12.6%) of IBD compared to sons (7.9%). Similarly, the 
female first-degree relatives of CD probands had a higher risk of IBD than their male counterparts. As 
there is a high degree of gene sharing between the affected individual and the first-degree relatives, 
these studies strongly suggested a pivotal role for genes in the etiology of IBD. 
3.5.2. Twin studies 
Twin studies are a powerful tool, often used in complex diseases, to better understand the 
contribution of genes and environmental factors in disease etiology. The twin studies are useful for 
determining if something is genetic, and making estimates for how heritable the disease is. 
Monozygotic twin pairs are genetically very similar, but not 100% identical because of spontaneous 
mutations or epigenetic modifications in the womb or after birth (Fraga et al. 2005). Dizygotic twins, 
on the other hand, are genetically equivalent to siblings but born at the same time and share only 
50% of their genetic material. Thus, in a monogenic disease with a very high penetrance, a close to 
100% concordance rate would be expected between monozygotic twins and a 50% concordance rate 
between dizygotic twins. However, if a disease is caused by environmental factors, both identical 
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and non-identical twin pairs would have the same concordance rates. The reported concordance 
rates for monozygotic twins and dizygotic twins are different and also differ among different studies. 
The first twin study on 80 unselected, same sex twins with IBD was performed in Sweden (Tysk et al. 
1988) and a concordance rate of 6.3% and 44.4% was reported for UC and CD respectively for 
identical twins. The corresponding numbers for non-identical twins were zero percent and 3.9%, 
respectively. In other studies, the monozygotic concordance rates for CD ranges from 20% to 55%  
and those for dizygotic twins are between zero and 6.5% (Orholm et al. 1991, Tysk et al. 1988, 
Halfvarson 2011, Halfvarson et al. 2006, Halfvarson et al. 2003, Thompson et al. 1996, Spehlmann et 
al. 2008). The concordance rates for UC for monozygotic and dizygotic twin pairs have been reported 
to range from 6.3% to 16-7% and from 0.0% to 6.3%, respectively. However, similar to earlier 
population-based studies, twin studies also suggest that genetic influence in CD is stronger 
compared to UC (Halfvarson 2011, Brant 2011). 
3.5.3. Linkage studies in IBD 
The familial aggregation and higher prevalence in first-degree relatives of IBD, than in the general 
population, encouraged the scientific community to look for susceptibility genes enriched in families 
where multiple members across different generations are affected. As a result of several linkage 
scans performed in different populations, many genomic regions have been implicated in CD, UC or 
IBD in general. The results from the first linkage scan (Hugot et al. 1996) were published in 1996 
suggesting a putative CD-susceptibility locus on chromosome 16q12 (IBD1). Some studies have 
confirmed linkage to IBD at this locus (Cho et al. 1997, Curran et al. 1998, Mirza et al. 1998) whereas 
other studies did not find any evidence of linkage (Olavesen et al. 2000, Rioux et al. 1998). In the 
same year, the second linkage scan (Satsangi et al. 1996) was performed on 186 affected sibling 
pairs, belonging to 160 nuclear families. All the study subjects in this study were UK resident 
Caucasians. The results of this study suggested the presence of additional susceptibility loci for both 
CD and UC on chromosomes 3p26 (IBD9) and 12p13.2-q24.1 (IBD2). The linkage at IBD9 locus 
(Curran et al. 1998, Rioux et al. 2000) and IBD2 locus (Hampe et al. 2001, Paavola et al. 2001) was 
later replicated in independent studies conducted in the European and North American populations. 
Nevertheless, studies conducted in Canadian (Rioux et al. 1998), Belgian (Vermeire et al. 2000) and 
French (Lesage et al. 2000) populations reported no evidence for linkage to IBD2 and IBD9 genomic 
regions raising the possibility that these loci may not be susceptibility loci in all populations. In a 
study by Cho et al. (174 families and 297 CD, UC or mixed relative pairs), evidence for linkage at 
chromosomal regions 4q (IBD4), 3q and 1p36 (IBD7) was observed (Cho et al. 1998).  
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Other regions identified by different linkage scans are the IBD3 locus on chromosome 6p (Hampe et 
al. 1999b, Hampe et al. 1999a), the IBD5 locus on chromosome 5q31 (Ma et al. 1999)) and the IBD6 
locus on chromosome 19p13 (Rioux et al. 2000). The large linkage region on chromosome 16 
motivated Hampe et al. to hypothesize that an additional risk gene may exist on this chromosome 
(Hampe et al. 2002). In a high-density experiment, using 39 microsatellite markers, a distinct locus 
on chromosome 16p (IBD8) was identified. The genomic regions with linkage to IBD identified in 
these studies have been replicated in several other studies (Duerr et al. 1998, Ma et al. 1999, 
Vermeire et al. 2004, Barmada et al. 2004, Paavola-Sakki et al. 2003, Williams et al. 2002, Duerr et al. 
2000). However, efforts to find susceptibility genes in the many genomic regions identified by 
linkage studies have mostly met with disappointment. The linkage studies described here are 
summarized in Table 4. 
Table 4. Linkage studies in IBD. 
Locus/Chromosome Reference 
IBD1 (16q12) (Hugot et al. 1996, Cho et al. 1997, Curran et al. 1998, Mirza et al. 
1998, Annese et al. 1999)(Olavesen et al. 2000, Rioux et al. 1998) 
IBD2 (12p13.2-q24.1) (Duerr et al. 1998, Curran et al. 1998, Hampe et al. 2001, Paavola 
et al. 2001)(Rioux et al. 1998, Vermeire et al. 2000, Lesage et al. 
2000) 
IBD3 (6p) (Hampe et al. 1999b, Hampe et al. 1999a) 
IBD4 (4q11-q12) (Cho et al. 1998) 
IBD5 (5q31) (Rioux et al. 2000, Ma et al. 1999) 
IBD6 (19p13) (Rioux et al. 2000) 
IBD7 (1p36) (Cho et al. 1998) 
IBD8 (16p) (Curran et al. 1998, Hampe et al. 2002) 
IBD9 (3p26) (Curran et al. 1998, Rioux et al. 2000) 
underlined: no evidence for linkage 
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3.5.4. Association studies in IBD 
In contrast to the linkage studies, association studies have been more promising. This approach has 
led to the identification of several susceptibility loci in IBD. The IBD1 locus on chromosome 16 was 
identified in the first genome-wide linkage scan (Hugot et al. 1996). In a separate study using a 
positional-cloning strategy, Hugot et al. identified three independent associations for CD (Hugot et 
al. 2001). The three associated NOD2 variants are R702W, G908R and 1007fs, where the first two are 
missense variants and the latter is a frame-shift mutation and the most significant of all three. 
Independently, Ogura et al. reported a cytosine insertion at nucleotide 3020 (3020insC) in exon 11 of 
the NOD2 gene resulting in a frame-shift at the second nucleotide of codon 1007, as previously 
reported by Hugot et al. (Ogura et al. 2001). The caspase recruitment domain-containing protein 
15/nucleotide-binding oligomerization domain protein 2 (CARD15/NOD2) gene lies in this genomic 
region, with mutations in this gene being associated with susceptibility of CD (Ogura et al. 2001). The 
first GWAS was performed in 2005 in IBD patients from Japan and the United Kingdom (Yamazaki et 
al. 2005). This study identified variations in the tumor necrosis factor superfamily, member 15 
(TNFSF15) gene which conferred IBD susceptibility in these populations. This association was later 
replicated in some studies but could not be established in others (Picornell et al. 2007, Thiebaut et 
al. 2009). Nonetheless, GWAS proved to be a fairly successful method as several associations were 
reported in the following years. A highly significant association between the IL-23 receptor (IL-23R) 
gene and CD was reported in a study consisting of cases and controls of European descent (Duerr et 
al. 2006) and further studies in IBD families revealed that this gene was also associated with UC in 
non-Jewish Caucasians. This finding has been successfully replicated in different populations 
(Libioulle et al. 2007, Raelson et al. 2007, Wellcome Trust Case Control Consortium 2007). Other 
genes which have been reported to be associated with IBD in different CD GWAS are prostaglandin 
receptor 4, EP4 subtype (PTGER4) (Libioulle et al. 2007, Wellcome Trust Case Control Consortium 
2007, Rioux et al. 2007), immunity-related GTPase family M (IRGM) (Wellcome Trust Case Control 
Consortium 2007) and protein-tyrosine phosphatase, non-receptor type 2 (PTPN2) (Wellcome Trust 
Case Control Consortium 2007). Together with IL23R gene, the autophagy 16-like 1 (ATG16L1) gene 
is the most replicated gene, although the association of ATG16L1 is mainly with CD and not with UC 
(Wellcome Trust Case Control Consortium 2007, Hampe et al. 2007). Previous studies in IBD families 
and twin studies had suggested that the genetic component is stronger in CD. Perhaps for that 
reason, more GWAS have been performed in CD than in UC. Nevertheless, in contrast to the strong 
association of ATG16L1 with CD, a SNP (rs3024505) in the vicinity of IL-10 was strongly associated 
with UC in a GWAS on multiple populations of European descent (Franke et al. 2008). In another 
GWAS (Silverberg et al. 2009), loci on chromosome 1p36 and 12q15 showing significant association 
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with UC were identified. Multiple genes involved in inflammation and immunity are present in this 
region. In addition, an association between UC and IL23R and the MHC region was independently 
verified in this study. It was earlier thought that UC might be a milder form of CD and when only 
some of the CD-specific genes are present UC may result. It has now been recognized that UC and CD 
are two closely related but distinct disorders of the gut. The two diseases share many risk genes, but 
also have a number of disease-specific risk genes. In a GWAS comprising 2693 UC patients and 6791 
control subjects, all of European ancestry, McGovern et al. identified several novel UC susceptibility 
loci and confirmed association with previously reported loci (McGovern et al. 2010a). Furthermore, 
several CD risk genes were also found to be associated with UC. Genome-wide association studies 
have also been performed to identify genes important in pediatric UC and early onset UC (Imielinski 
et al. 2009, Kugathasan et al. 2008).  
 As is the case with complex diseases, many genes contribute to a disease risk but the contribution of 
a single gene may be small. Meta-analyses have been quite useful in identifying low-risk genes by 
using the cumulative power of several different GWAS. In a CD meta-analysis, 71 confirmed SNP 
associations were reported (Franke et al. 2010). A meta-analysis in UC led to an increased number of 
confirmed SNP associations, from 29 to 47 (Anderson et al. 2011) with a significant overlap with CD. 
Recently, an imputation-based association analysis of a large number of UC and CD GWAS using 1.23 
million SNPs and a subsequent meta-analysis with Immunochip validation was performed (Jostins et 
al. 2012). This study identified 71 new IBD associations, taking the total number to 163. One 
hundred ten of the total 163 loci are associated with both CD and UC, 30 loci are CD specific and 23 
loci are UC specific. Collectively, these loci explain only a minority of the variance in the disease risk 
(< 15% for CD and < 8% in UC) (Jostins et al. 2012) suggesting a bigger role for rare genetic variants 
and other experimental risk factors. A systematic review and meta-analysis of data from 93 
previously published studies (in different Asian populations) revealed that there are major 
differences in IBD risk genes in Western and Asian countries (Ng et al. 2012). For instance, major 
NOD-2 variants that are associated with CD in Western countries are not associated with CD in Asian 
populations studied in this study. However, other population-specific NOD-2 variants were reported 
to exist. This demonstrates that population-specific differences in risk genes are likely to exist. The 
association studies described above are tabulated in Table 5. 
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Table 5. Association studies in IBD. 
Loci/Genes identified or investigated References 
IBD1/NOD2 (16q12) (Hugot et al. 2001, Ogura et al. 2001) 
TNFSF15 (9q32) 
(Yamazaki et al. 2005, Picornell et al. 2007, Thiebaut et 
al. 2009) 
IL23R (1p31.3) 
(Duerr et al. 2006, Libioulle et al. 2007, Raelson et al. 
2007, Wellcome Trust Case Control Consortium 2007) 
PTGER4 (5p13.1) 
(Libioulle et al. 2007, Wellcome Trust Case Control 
Consortium 2007, Rioux et al. 2007) 
IRGM (5q33.1) (Wellcome Trust Case Control Consortium 2007) 
PTPN2 (18p11.3-11.2) (Wellcome Trust Case Control Consortium 2007) 
ATG16L1 (2q37.1) 
(Wellcome Trust Case Control Consortium 2007, 
Hampe et al. 2007) 
IL10 (1q31-q32), ARPC2 (2q35) (Franke et al. 2008) 
IBD7 (1p36) and 12q15, multiple 
genes (Silverberg et al. 2009) 
Multiple UC susceptibility loci 
(Jostins et al. 2012, Anderson et al. 2011, McGovern et 
al. 2010a) 
Multiple CD susceptibility loci (Jostins et al. 2012, Franke et al. 2010) 
 
3.6. Pathogenesis of IBD 
In the past few years, immense knowledge has been gained regarding genetic and environmental 
factors important in the onset of IBD, but despite this progress the pathogenesis of IBD remains 
elusive. There is however a general consensus now that IBD may be a result of an inappropriate and 
continuous inflammatory response to commensal gut microbes in genetically susceptible individuals. 
Genes identified in different genetic studies (Jostins et al. 2012, Anderson et al. 2011, Franke et al. 
2010, Franke et al. 2008) suggest several cellular pathways that are crucial in intestinal homeostasis 
including innate and adaptive immune regulation, epithelial restitution, microbial defense, reactive 
oxygen species (ROS) generation, endoplasmic reticulum (ER) stress and autophagy (Khor, Gardet & 
Xavier 2011, Maloy, Powrie 2011). The CD susceptibility gene CARD15/NOD2 encodes a protein 
which belongs to a family of intracellular proteins that contain an N-terminal caspase recruitment 
domain (CARD), a centrally located nucleotide-binding domain (NBD) and a C-terminal regulatory 
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leucine-rich repeat (LRR) domain (Ogura et al. 2001). NOD2 acts as an intracellular receptor for 
bacterial products in different cell types and transduces signals leading to NFkB activation and plays 
a key role in innate immune activation (Strober et al. 2006, Creagh, O'Neill 2006). The frame-shift 
mutation- 1007fs- results in the Leu1007Pro substitution in the tenth LRR of the NOD2 protein 
followed by a premature stop codon and a truncated protein (Ogura et al. 2001). Cooney et al. 
showed that the stimulation of NOD2 by muramyldipeptide induces autophagy in dendritic cells 
(Cooney et al. 2010). This effect is dependent on, among others, the ATG16L1 protein, which is a 
product of the CD associated ATG16L1 gene. Furthermore, DCs from CD individuals with NOD2 or 
ATG16L1 risk variants are defective in autophagy induction, bacterial trafficking and antigen 
presentation. This further underscores the importance of a dysregulated immune response towards 
commensal gut flora in IBD pathogenesis (Ordas et al. 2012, Frank et al. 2011).  
The inflammation in IBD starts as a result of defects in the components of the innate immune 
system, but the adaptive immune system is mainly responsible for maintaining the subsequent 
chronic inflammatory state. In both UC and CD, the balance between Treg cells and effector T cells, 
i.e. Th1, Th2 and Th17 CD4+ T cells is perturbed (Ordas et al. 2012, Baumgart, Sandborn 2012). In UC, 
an atypical Th2 type adaptive immune response predominates. This response is mediated by IL-5 and 
IL-13 secreting non-classical NK cells. Interleukin-13 has cytotoxic effects on IECs, such as the 
induction of apoptosis and alteration in the TJ proteins (Heller et al. 2005, Heller et al. 2008). In 
contrast, the mucosal inflammation in CD is a result of Th1 and Th17 immune responses (Hisamatsu 
et al. 2012, Sakuraba et al. 2009). Several genes that have been identified participate in the 
regulation of adaptive immune response (Jostins et al. 2012). The delineation of the exact 
mechanisms leading to impaired gut mucosal homeostasis warrants further research.  
3.7. Diagnosis and treatment 
According to the guidelines for the diagnosis and management of IBD, issued by the World 
Gastroenterology Organization, diagnosis of IBD is made on the basis of medical history, physical 
examination, laboratory and microbial (stool cultures) studies, histological examinations, endoscopy, 
imaging studies and consultation with other specialists for extraintestinal symptoms. The diagnosis 
should not be made or excluded on the basis of one variable or result. Other diseases that mimic CD 
or UC require extra care and must be ruled out. Ulcerative colitis and CD are closely related and may 
be difficult to differentiate during the initial disease course. However, several features (clinical, 
endoscopic and radiological, histopathological and serological markers) have been outlined to ease 
their identification (Bernstein et al. 2010). Once a diagnosis has been established, patients are 
phenotyped according to the Montreal classification criteria (Silverberg et al. 2005) and screened for 
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extraintestinal manifestations and associated autoimmune diseases. The treatment regimen in IBD 
depends on disease course, extent of inflammation and disease severity. However, the general 
treatment goals are to improve and maintain the general well-being of patients, treatment of acute 
disease, maintain steroid-free remissions, prevent complications, hospitalizations and surgery and 
maintain good nutritional status (Bernstein et al. 2010). Drugs that are used in IBD management 
include aminosalicylates (anti-inflammatory drugs), corticosteroids, immune modifiers, anti-TNF 
agents and antibiotics. Probiotics, different experimental agents in UC and CD (antiadhesion 
molecules, anticytokine therapies etc.) and symptomatic therapies may also be used to treat the 
subject. In about 70%-75% of the CD cases, surgery is required at some point to relieve the 
symptoms if the drug treatment is unsuccessful. In 25%-30% of UC patients, surgery is performed if 
the patient is not responding to medical treatment or in the presence of dysplasia. However, in 
contrast to surgery in CD, surgical resection in UC is considered curative for the disease (Bernstein et 
al. 2010).  
4. Gut microbiota, immune system and susceptibility to different diseases 
Our immune system evolved to protect us from harmful pathogens that surround us. Yet, our body is 
a host to numerous microbes that inhabit the gut and skin surface. It is estimated that the human 
gut is home to approximately 1014 microorganisms, which is ten times the number of cells in our 
body (Bjorksten et al. 2001, Sears 2005). Over the course of human evolution, a symbiotic 
relationship has evolved between humans and the gut resident microorganisms. The human host 
provides nutrition and habitat to these microbes and in return they perform various tasks in the gut, 
which our body is incapable of doing. It is a formidable task to identify all microbial species in the gut 
owing to inter-individual differences, challenges in their identification or because they cannot be 
cultured in the lab (Sears 2005, Guarner, Malagelada 2003). In general, human beings have a lot 
more anaerobic bacteria (100-1000 times) compared to aerobic bacteria (Guarner, Malagelada 2003) 
and every individual has several hundreds of species belonging to each genera. However, most gut 
bacteria belong to the genera Bacteroides, Clostridium, Bifidobacterium, Peptostreptococcus, 
Pepticoccus, Eubacterium, Ruminococcus and Fusobacterium (Guarner, Malagelada 2003, Beaugerie, 
Petit 2004). The subdominant genera include aerobic (or facultative anaerobic) bacteria such as 
escherichia, enterobacter, enterococcus, klebsiella, lactobacillus and proteus among others. Tap et 
al. studied the composition of gut microbiota in fecal samples from 17 healthy individuals (Tap et al. 
2009). They found that a small number of operational taxonomic units (OTUs) were present in over 
fifty percent of studied individuals and suggested that a core gut microbiota may exist in all 
individuals. The microbiota compositon of newborns differ from that of grown-ups. At birth, the 
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infant gut is mainly colonized with facultative aerobic bacteria, including streptococci and 
Escherichia coli, which at weaning shift towards obligate anaerobic composition of genera 
Bifidobacterium, Bacteroides, Clostridium and Ruminococcus (Sears 2005).  
Microorganisms perform an array of functions for their host. For example bacteria ferment the non-
digestible complex dietary carbohydrates and mucus produced by epithelial cells into short chain 
fatty acids (SCFAs) (Sears 2005, Guarner, Malagelada 2003). This digestion process is aided by 
different enzymes collectively present in distinct microbial species in the colon. The SCFAs are a 
major source of useful energy and nutrition for the host and also help in the absorption of dietary 
minerals like calcium, magnesium and iron (Guarner, Malagelada 2003). In addition to its role in 
nutrition management, the microbiota is important for the maintenance of epithelial homeostasis. 
Germ-free rats have fewer cells in the crypts compared to rats housed under normal conditions, a 
feature which has been attributed to the lack of normal commensal bacteria (Gordon et al. 1997, 
Alam, Midtvedt & Uribe 1994). The SCFAs produced by bacteria during carbohydrate metabolism 
stimulate epithelial cell proliferation and differentiation in the small- and large intestine and aid in 
intestinal homeostasis (Frankel et al. 1994, Siavoshian et al. 2000). 
Microorganisms are present in great numbers in the gut so they must compete with each other for 
an attachment site or nutrients. Such a competition is known as a barrier effect which serves to 
protect the host from colonization by pathogenic or opportunistic bacteria (Guarner, Malagelada 
2003). There is some evidence that commensal bacteria can inhibit the growth of their competitors 
by producing toxins, called bacteriocins (Lievin et al. 2000). It is thus quite evident that a harmonious 
relationship with gut microbiota is crucial to our well-being. A disturbance in this relationship usually 
leads to health complications for the host. In case of a bacterial translocation, bacterial toxins or 
viable bacteria can cross the intestinal epithelial barrier and spread throughout the body and cause 
sepsis, shock, multisystem organ failure or the death of the host (Guarner, Malagelada 2003). 
Bacterial translocation is caused by three main mechanisms, namely overgrowth of bacteria in the 
small intestine, increased permeability of the intestinal epithelial barrier and deficiencies or defects 
in the host immune system. In human disorders such as multisystem organ failure, acute severe 
pancreatitis, advanced liver cirrhosis, intestinal obstruction and IBD, rates of positive mesenteric 
lymph node culture are 16%-40% , which in healthy individuals are below 5% (Lievin et al. 2000).  
Studies in animal models show that gut microbiota is essential for proper development of the host 
immune system. Mice kept under germ-free conditions have an underdeveloped mucosal immune 
system with small lymphoid follicles, few IgA-secreting plasma cells and reduced submucosal T-cell 
populations, including CD4+ and intraepithelial CD8+ T lymphocytes (Macpherson, Uhr 2004a, 
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Macdonald, Monteleone 2005). Furthermore, studies on germ-free mice and specific-pathogen-free 
(SPF) mice demonstrate impaired ability of germ-free mice to clear infection compared to SPF mice 
(Inagaki et al. 1996). Rakoff-Nahoum et al. showed that toll-like receptors (TLRs), which play an 
important role in protection from infections caused by microbes, recognize and interact with 
commensal bacteria (Rakoff-Nahoum et al. 2004). This interaction is critical to host protection from 
gut injury and associated mortality. Moreover, in a study by Ivanov et al. it was shown that specific 
intestinal microbiota directs the differentiation of IL-17 producing T-helper cells in small-intestinal 
mucosa and thus regulates the balance between Th17 and Treg cells in the lamina propria (Ivanov et 
al. 2008). Consequently, gut microbiota influences intestinal immunity and susceptibility to certain 
diseases. The modulation of intestinal microbiota was shown to delay the onset of T1D, and also 
causing a reduction in the incidence of T1D in germ-free non-obese diabetic mice (King, Sarvetnick 
2011).  
The interaction between the host immune system and commensal bacteria is particularly important 
in childhood or infancy when the immune system is developing. Interestingly, the gut microbiota 
plays an important role in modulating the adaptive immune system (Macdonald, Monteleone 2005). 
The GI tract plays an important role in the extrathymic development of T and B cell repertoires.  
Developing T cells and B cells are exposed to self-antigens in the thymus and bone-marrow 
respectively which ensures the induction of tolerance towards self-antigens. Similarly, the GI tract is 
the largest source of non-self, but innocuous antigens, derived from commensal bacteria. Dendritic 
cells have been shown to sample luminal bacterial antigens and present them to submucosal 
macrophages and T lymphocytes (Rescigno et al. 2001, Macpherson, Uhr 2004b). This process is 
considered important in the induction of tolerance towards harmless environmental antigens. It is 
thus not surprising that an alteration in the gut microbiota has been reported in immunological 
diseases such as IBD (Andoh et al. 2011, Thomazini et al. 2011, Sokol et al. 2006, Macia et al. 2012), 
CelD (Macia et al. 2012, Schippa et al. 2010, Nistal et al. 2011), T1D (King, Sarvetnick 2011, Macia et 
al. 2012, Hara et al. 2013), hepatitis B virus-induced chronic liver disease (Xu et al. 2011), RA and 
asthma (Macia et al. 2012). An allergic reaction is a result of an overreaction of the immune system 
to innocuous environmental antigens. Reduced diversity in the composition of gut microbiota during 
infancy and childhood was found to be associated with increased risk for allergies at later ages 
(Bjorksten et al. 2001, Johansson et al. 2011, Bisgaard et al. 2011). In a study, an early colonization 
with a group of lactobacilli was able to decrease the risk for allergy in five-year old children, despite 
genetic predisposition for allergy in these children (Johansson et al. 2011). In another study, early 
intervention with probiotics and prebiotics did not affect the risk for airway inflammation later in 
childhood (Kukkonen et al. 2011). Alterations in the gut microbiota have been reported in systemic 
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diseases such as obesity (Million et al. 2011) and type-2 diabetes (T2D) (Brown et al. 2012) which are 
primarily metabolic disorders. This suggests that changes in gut microbiota may have implications 
beyond immunological diseases. 
It was earlier thought that the composition of intestinal microbiota stayed relatively stable after 
colonization in early childhood. However, several studies now speak against this concept and a clear 
picture of dietary factors that can affect intestinal microbial composition is starting to emerge. The 
colonization of the GI tract with microbes in newborns starts already at birth and its composition is 
highly dependent on the mode of delivery. There are significant differences in the microbiota 
composition in infants who were delivered through birth canal compared to those who were born 
through caesarean section (Guarner, Malagelada 2003, Penders et al. 2006). Other factors that affect 
the diversity of gut microbiota are the type of diet (i.e. breast feeding or formula feeding), age, 
infant hospitalization, stress, degree of hygiene and antibiotic use by the infant (Brown et al. 2012, 
Penders et al. 2006). Furthermore, diet rich in fat and sugar results in microbiota which is distinct 
from microbiota promoted by a diet which is rich in carbohydrate and low in fat and sugar (Brown et 
al. 2012).  
As assessed by a study in mice, the gut microbiota is to a large extent (57%) determined by diet and, 
interestingly, also to a smaller extent (12%) by host genetics (Zhang et al. 2010). A potential 
relationship between host genetics and gut microbiota was suggested already in the early 1980s 
(Wensinck et al. 1981, Van de Merwe, Stegeman & Hazenberg 1983). These studies reported that 
the fecal microbiota of CD patients was different from that of healthy subjects in composition and 
that there was a significantly higher degree of similarity in fecal microbiota of healthy monozygotic 
twin pairs compared to that of dizygotic twin pairs. A more recent study demonstrated a higher 
degree of fecal microbiota similarity between healthy monozygotic twins than in monozygotic twins 
with CD (Dicksved et al. 2008). A significant difference in microbiota composition between healthy 
individuals and patients with ileal CD has also been reported. In another study, Stewart et al. 
investigated the genetic basis for predominance of eubacteria in fecal microbiota in twin pairs 
(Stewart, Chadwick & Murray 2005). The highest degree of similarity was found between 
monozygotic twins followed by dizygotic twins and the least amount of similarity was found 
between unrelated control individuals. Although many family and twin studies established the 
involvement of genetic component in microbiota composition, fewer studies have identified genes 
involved in microbial colonization.  
Mutations in the NOD2/CARD15 gene are associated with increased risk for CD and have also been 
associated with a shift in microbial composition in the ileum (Li et al. 2012). Furthermore, genetic 
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variants in the genes TLR4 and CD14 have been shown to confer increased risk for CD (Gewirtz et al. 
2006) and atopic diseases (Penders et al. 2010). The HLA region is of utmost importance in CelD and 
HLA-DQ2 genotype has been reported to influence the composition of commensal bacteria, both in 
humans and mice (Sanchez et al. 2011, Toivanen, Vaahtovuo & Eerola 2001). The fucosyltransferase 
2 (FUT2) gene is present on 19q13.33 and is associated with both alterations in the microbiota and 
risk or protection from various diseases. The product of the FUT2 gene is an enzyme (α-1,2-
fucosyltransferase) which participates in the conversion of type 1 precursor to type 1 H antigen by 
adding a terminal α1,2-linked fucose to galactose on type 1 precursor. The type 1 H antigen is the 
precursor for the further synthesis of A and B blood group antigens which is carried out by A- and B- 
transferases respectively (Combs 2009).  
Figure 5. The figure shows the biosynthesis of A, B and H blood group antigens. 
These antigens are also expressed in the GI mucosa where they serve as anchors for various 
microbes. In 20% of Caucasians, this gene is rendered nonfunctional by a nonsense mutation at 
nucleotide 428, introducing a premature stop codon at position 143 (G428A, W143X) (Kelly et al. 
1995, Soejima, Koda 2005). Individuals who are homozygous for this mutation are called non-
secretors (se428, rs601338-AA). Although the prevalence of non-secretor status is fairly similar 
among different populations, different mutations leading to the non-secretor status have been 
identified (Soejima, Koda 2005). For example, the allele se428 (G428A, W143X) is the causative 
variant in Europeans, Iranians and Africans, whereas another allelic variant se385 (A385T, 
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rs1047781) is associated with the non-secretor status in South-East and East-Asians (Ferrer-Admetlla 
et al. 2009). As FUT2 gene controls the expression of ABH and Lewis histo-blood group antigens, it is 
conceivable that it may also affect the composition of microbiota. In a study by Wacklin et al., a 
significant reduction in bifidobacterial diversity, richness and abundance was observed in fecal 
microbiota from healthy non-secretors compared to secretors (Wacklin et al. 2011). Consistent with 
the role of gut microbiota in modulating innate- and adaptive immune responses, both secretor and 
non-secretor status are associated with increased risk for or protection from certain diseases. For 
example, non-secretor individuals show increased susceptibility to duodenal ulcers (Evans et al. 
1968), rheumatic fever (Haverkorn, Goslings 1969) and cholera (Chaudhuri, DasAdhikary 1978), but 
they are resistant to infections from Norovirus (Lindesmith et al. 2003, Carlsson et al. 2009) and 
respiratory viruses (Raza et al. 1991). Similarly, secretors are more susceptible to Helicobacter pylori 
infection (Linden et al. 2008) but the breast milk of secretor mothers confers protection against 
Campylobacter jejuni to the offspring (Ruiz-Palacios et al. 2003). Furthermore, FUT2 non-secretor 
status has been associated with increased risk for CD (McGovern et al. 2010b) and T1D (Smyth et al. 
2011) in Caucasians. In a study by Rausch et al., which included healthy control individuals and 
individuals affected with CD, the FUT2 genotype was found to affect the microbiota associated with 
colonic mucosa (Rausch et al. 2011). In light of these studies, it seems tempting to assume that both 
environmental factors, such as diet and life style, and the genetic architecture of an individual define 
the composition of gut microbiota.  
5. Transcriptomics: scope and methods 
The information required for proper functioning of an organism is encoded in its genome. This 
information is extracted by gene transcription and expressed through the process of gene 
translation. The transcriptome is the complete set of RNA [messenger RNA (mRNA), transfer RNA 
(tRNA), ribosomal RNA (rRNA) and other non-coding RNA] transcripts produced by gene 
transcription at any given time. During an organism’s life time, the genomic content remains largely 
unchanged and does not vary according to the cell type, stage of development or environmental 
conditions. In contrast, the transcriptome is highly dynamic and its composition may differ in 
different cells or in the same cell at different time points or under different conditions. The study of 
transcriptome produced by the genome at a given time is referred to as transcriptomics. 
Transcriptomics can be used to investigate differential gene expression patterns in cells at different 
developmental stages (Assou et al. 2011), to unravel the gene interaction network (Alekseev et al. 
2009), to discover genes abnormally expressed in a disease (Wang et al. 2013, Min et al. 2009), to 
identify drug targets (Cheung 2007) etc. Several hybridization-based methods (Northern blotting, 
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DNA microarrays), polymerase chain reaction (PCR)-based methods (differential display and 
representational difference analysis) and sequence-based techniques (expressed sequence tags 
(ESTs), serial analysis of gene expression (SAGE)) have been used in gene expression studies (Kozian, 
Kirschbaum 1999, Fryer et al. 2002). Although all these methods have inherent advantages and 
limitations (relating to expense, technical difficulty, sensitivity and specificity), the microarray 
technology has been widely used. Recent technological advances have also made possible the use of 
sequencing techniques, such as exome sequencing (Ng et al. 2009) and RNA sequencing (Wang, 
Gerstein & Snyder 2009) in gene expression studies. Nevertheless, these methods are still quite 
expensive and due to a large amount of data produced also present with some technical and 
bioinformatics-related challenges. 
6. Several risk genes are shared among different immunological diseases 
As discussed in sections 2.6 and 2.8, individuals suffering from CelD and DH have an increased risk 
for developing other autoimmune diseases. This suggests that same genes or same pathways are 
responsible for causing different autoimmune/immune-mediated diseases. Indeed, recent research 
has shown that many genes are shared across different immunological diseases. Susceptibility genes 
in CelD have been shown to also confer risk to other autoimmune diseases such as T1D (Smyth et al. 
2008), RA (Coenen et al. 2009) and CD (Festen et al. 2011). Among many others, shared genetic 
background between RA and T1D (Alizadeh et al. 2007, Zhernakova et al. 2007, Eyre et al. 2010), 
between CD and psoriasis (Ellinghaus et al. 2012) and between CD and UC (Jostins et al. 2012, Glas et 
al. 2012, Waterman et al. 2011) has been reported. Cotsapas et al. studied the extent of sharing for 
107 immune-disease risk SNPs in seven immunological diseases (Cotsapas et al. 2011). They found 
that 47 of 107 disease risk loci were associated with multiple but not all diseases that were under 
investigation. A detailed overview of shared genetics between IBD and several other diseases has 
been provided in a review by Lees et al. (Lees et al. 2011). Undoubtedly, to look for shared genetics 
between similar diseases is an effective method as it is both economical and time saving.  
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Aims of this study 
CelD and IBD are inflammatory disorders where both genetic and environmental factors contribute 
to disease pathogenesis. This study was conducted to identify genes which are affected by 
environmental factors (gliadin peptides) as well as to identify genes which affect environmental 
factors (gut microbiota). Furthermore, genes involved in the regulation of innate and adaptive 
immune system are likely to be shared by different immunological diseases. Both CelD and IBD are 
immunological diseases of the gut, efforts were made to identify CelD genes which may also confer 
susceptibility to IBD in the Finnish population. The specific aims of this study were: 
1. To use microarray chips to obtain a gene expression profile of intestinal epithelial Caco-2 
cells stimulated with gliadin in order to gain insight into the activation of different receptor-
dependent or –independent pathways. These pathways may help us understand the gliadin 
mediated early steps in disease progression. 
2. To study the association of secretor/non-secretor status (FUT2 rs601338 polymorphism) 
with CelD and IBD in the Finnish population. The FUT2 genotype affects the composition of 
gut microbiota and may therefore associate with the risk of these diseases. 
3. To explore the shared genetic background of CelD and IBD by investigating whether the 
recently identified CelD risk loci also affect susceptibility of IBD. 
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Material and methods 
1. Digestion of gliadin, bovine serum albumin and lactalbumin  
 Wheat flour (Raisio Oyj, Raisio, Finland) was obtained from a local grocery store. Bovine serum 
albumin (BSA), lactalbumin, pepsin (P-6887) and trypsin (T-7418) were obtained from Sigma-Aldrich 
(Sigma-Aldrich, Seelze, Germany). The method for the extraction of gliadin from wheat and for the 
digestion of gliadin, BSA and lactalbumin with pepsin and trypsin is described below. At the same 
time and using the same reagents, a blank pepsin and trypsin control (PT) was prepared where no 
substrate was used for digestion. For simplicity, the method below describes the digestion of gliadin 
only. The pepsin- and trypsin- digested gliadin, BSA and lactalbumin are denoted PT-G, PT-BSA and 
PT-L. 
Whole gliadin was first extracted from wheat flour. To remove salt-soluble proteins, 10g of wheat 
flour was dissolved in 30ml 1M NaCl and incubated at room temperature for one hour on a shaker. 
This was followed by centrifugation at 4000g for 20 minutes. The pellet was washed with 40ml water 
and centrifuged at 4000g for 20 minutes. The pellet was then suspended in 25ml 70% ethanol 
followed by incubation at 60°C for one hour with shaking. After one hour, supernatant containing 
the gliadin fraction was collected by centrifugation, frozen and lyophilized.  
For digestion by pepsin, 60mg gliadin was dissolved in 10ml 50mM NaAc buffer (pH 4.0) and 3mg 
pepsin (P-6887, Sigma-Aldrich) was added to the solution. The mixture was incubated at 37°C for 
two hours on a shaker. Seventy one milligrams of Na2HPO4 was added to the solution and the pH 
was adjusted to 7.0 with NaOH. For digestion with trypsin, 3mg trypsin (T-7418, Sigma-Aldrich) was 
added to the mixture followed by incubation at 37°C for two hours on a shaker. The digestion 
solution was heated at >95°C for ten minutes to stop digestion reactions. The pepsin- and trypsin- 
digested gliadin (PT-G) mix was then frozen, lyophilized and stored at -20°C for later use. 
2. Caco-2 cell cultures and stimulations 
The human colon carcinoma cell line, Caco-2, was used to study the effect of gliadin peptides on 
small-intestinal epithelial cells. Despite the colonic origin of Caco-2 cells, when cultured under 
specific conditions their phenotype, morphologically and functionally, resembles that of enterocytes 
lining the small intestine (Hidalgo, Raub & Borchardt 1989). Caco-2 cells were maintained in 
minimum essential medium (MEM, Invitrogen, Carlsbad, CA, USA) to which 1X sodium pyruvate 
(NaPy 100X, Invitrogen), 1% penicillin-streptomycin (Pen-Strep, Invitrogen), 1X non-essential amino 
acids (100X NEAA, Invitrogen) and 10% fetal calf serum (FCS, PROMOCELL GmbH, Heidelberg, 
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Germany) were added. The cells were kept in an incubator at 37°C with 5% carbon dioxide. The 
pepsin- and –trypsin (PT) blank control, PT-BSA, PT-L, PT-G and the synthetic peptides p31-43 
(LGQQQPFPPQQPY) and p57-68 (QLQPFPQPQLPY) (both obtained from New England Peptide LLC, 
Gardner, MA, USA) were dissolved in MEM + 1% FCS and sterilized by passing through 0.22µm pore 
filter (Millipore, Billerica, MA, USA). An endotoxin test (Limulus Amebocyte Lysate (LAL), Pyrogent 
plus single test kit, CAMBREX, East Rutherford, NJ, USA) confirmed the presence of endotixin in PT-
BSA, but not in PT-G. For stimulation, 3x105 cells were seeded in 3ml MEM + 1% FCS in 25cm2 flasks 
at 37°C in an incubator with 5% carbon dioxide for three days. Before stimulations, the cells were 
washed once with phosphate-buffered saline (PBS) and stimulated with PT, PT-G, PT-BSA, PT-L, p31-
43 and p57-68 peptides in 2ml MEM + 1% FCS for six hours. The final concentration of PT, PT-BSA, 
PT-L and PT-G to which the cells were exposed was 1mg/ml, whereas that of synthetic peptides 
(p31-43 and p57-68) was 150µg/ml. PT, PT-BSA and PT-L were used as negative controls for PT-G 
treatment and p57-68 peptide was  used as a negative control for p31-43 stimulation. The control 
cells (MED-CTL) were kept in MEM + 1% FCS for six hours. The experiment was repeated four times 
to obtain four different biological replicates. The cells differed by 1-2 passages between each 
experiment.  
3. Cell collection and RNA extraction 
After the six hours stimulation time, cells were collected by adding 1ml 1X trypsin-EDTA (Trypsin 
10X, Invitrogen) to the flasks followed by incubation at 37°C for four to five minutes. Trypsin was 
inhibited by adding 1ml MEM + 10% FCS to the flasks followed by centrifugation at 9600xg for five 
minutes. The supernatant was discarded and the pellet was washed once with 500µl 1X PBS 
followed by another round of centrifugation. The supernatant was discarded and the pellet was 
stored at -80°C until later use. For RNA extraction, the pellet was thawed on ice and RNA extracted 
using RNeasy Plus Mini kit (Qiagen GmbH, Hilden, Germany) following the vendor’s instructions. RNA 
quality was assessed by bioanalyzer (2100 Bioanalyzer, Agilent, Santa Clara, CA, USA) 
4. Microarray hybridizations and data analysis 
RNA extracted from cells treated with PT, PT-G, MED-CTL and p31-43 peptide (from four different 
experiments) was used for hybridization on Agilent one color human whole genome DNA microarray 
chips (4x44K) (Agilent Technologies, Santa Clara, CA, USA). 600µg RNA was used for cDNA synthesis. 
The cDNA synthesis and subsequent hybridization on microarray chips were carried out at 
Biomedicum Genomics Support, Helsinki, Finland. Microarray raw data files were imported into R v. 
2.15 (Team 2012) and analyzed with BioConductor (Gentleman et al. 2004) package limma (Smyth 
2005). After the quality check, the microarray probes were filtered and re-annotated as previously 
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described (Gertz et al. 2009) and their median foreground intensity was normalized with the 
quantiles method without applying any background correction, as suggested by Zahurak et al. 
(Zahurak et al. 2007). After that, the probes were tested for differential expression using a linear 
model followed by a moderated t-test (Smyth 2005) for intended comparisons. All genes with p < 
0.01 were considered to be differentially expressed.  
5. Quantitative real-time polymerase chain reaction (qRT-PCR) 
Five genes differentially regulated in microarray data analysis, were selected for validation by qRT-
PCR. The selection criteria were high endogenous expression level (≥ log2 9.0) and a difference in 
fold change (FC) of ≥ 1.4 in either direction. One probe corresponding to the gene 
reticuloendotheliosis viral oncogene homolog A (RELA) did not fulfill the selection criteria. This gene 
was selected because of its involvement in the NFkB pathway and NFkB pathway is relevant in CelD 
pathogenesis (Maiuri et al. 2003b). Primers were designed using the primer designing software 
Primer express (Applied Biosystems Foster city, CA, USA) and are listed in Table 6. Complementary 
DNA (cDNA) was made from 300ng of RNA using reagents provided in the TaqMan Reverse 
Transcription Kit (Applied Biosystems, Foster city, CA, USA) and following the enclosed instructions. 
The qRT-PCR assay was performed on 7500 Fast Real-Time PCR System (Applied Biosystems, Foster 
city, CA, USA) using Power SYBR Green PCR Master Mix (Applied Biosystems) (1X SYBR Green PCR 
Master Mix and 0.6µM forward and reverse primer each). The qRT-PCR data were analyzed using the 
comparative C(T) method as described previously (Schmittgen, Livak 2008). The gene expression 
levels were normalized against beta-2 microglobulin (B2M) gene expression. 
 
  
Table 6. Primers used for qRT-PCR 
 Gene Forward (5'-3') Reverse (5'-3') 
B2M GTGCTCGCGCTACTCTCTC GTCAACTTCAATGTCGGAT 
CEBPa GACCCTCAGCCTTGTTTGTACTG CTGATCGTGCTTCGTGTTCCT 
KLF4 ACCAGGCACTACCGTAAACACA GCTCGGTCGCATTTTTGG 
MNF1 CACAGACACCTTGGAAGAGCTTAA GGGCAAACTTCTCCTGCAGTT 
RELA CAGGCGAGAGGAGCACAGA TGTGTAGCCATTGATCTTGATGGT 
SPRED1 TGAATGCTGCTACAACAGATGATC GAAAGTTAACAGTCTATTCTAGGAAACCAA 
B2M: Beta-2 microglobulin, CEBPa: CCAAT/enhancer binding protein alpha, KLF4: Kruppel-like factor 4,  MNF1: Mitochondrial 
nucleoid factor 1, SPRED1:  REL-A: v-rel reticuloendotheliosis viral oncogene homolog A,  Sprouty-related, EVH1 domain 
containing 1  
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6. DNA extraction 
Prior to the studies described here the genomic DNA was extracted from the EDTA whole blood 
samples of the CelD and IBD patients using the Flexigene DNA kit or the QIAamp DNA Blood Mini Kit 
(Qiagen GmbH, Hilden, Germany). 
7. Marker selection 
Association of only one SNP (rs601338-FUT2) was studied in Study II. The selection of this SNP was 
based on its association with CD in another Caucasian population (McGovern et al. 2010b) and also 
because genetic variants at this position affect the transcription of the FUT2 gene. In Study III, 
association of 45 SNPs with CD and/or UC was investigated based on their association with CelD in a 
previous multi-population CelD GWAS (Dubois et al. 2010). Thirty-nine of these SNPs were chosen 
because they represented the strongest associations from that GWAS. Six additional SNPs were 
included in Study III as they showed stronger association with CelD in the Finnish population at these 
loci, than the markers giving the top association signals in the multi-population analysis. All the SNPs 
investigated during this thesis work are listed in Table 7. 
8. Study subjects 
The collection of patient and control materials was approved by the ethics committee of Helsinki 
University Hospitals, Finnish National Public Health Institute and Tampere University Hospital. All the 
study subjects were informed about the study according to the study protocol and gave their written 
informed consent. In Study II, there were 943 unrelated CelD patients and an independent set of 119 
CelD patients who had DH (Table 8). Most of the CelD and DH patients in this study derive from a 
large family collection which includes probands and their first-degree relatives screened serologically 
for CelD associated autoantibodies (ATGA and/or EMA). Ninety-five percent of the Ab-positive CelD 
family members were also biopsy-proven CelD cases. Only one patient per family, the proband in 
most cases, was included in this study. Only unrelated individuals were included in the combined 
CelD + DH dataset. If a CelD patient and a DH patient belonged to the same family, one of them was 
randomly selected. Hence, the total number of patients in CelD + DH group is 1025. 
In the IBD dataset used in this study, there were 303 CD and 545 UC patients (Table 8). Thirty-one of 
the UC and CD affected individuals were related, thus one of the two was randomly selected to the 
IBD (CD + UC) group. After randomly removing one of the related UC and CD patients, there were a 
total of 745 unrelated individuals in the combined dataset group (i.e. IBD group). One thousand 
forty-five (1045) Finnish blood donor control samples were provided by the Finnish Red Cross Blood 
Service (Study II) and data for another 1693 control subjects were obtained from the second GWAS 
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in CelD by Dubois et al. (Dubois et al. 2010) (Studies II and III). The total number of controls in this 
study was thus 2738. 
Table 7. List of SNPs used in Study II and Study III. 
MARKER CHR POS 
(Mb) 
MARKER CHR POS 
(Mb) 
MARKER CHR POS 
(Mb) 
rs3748816 1 1.8 rs13098911 3 46.3 rs9792269 8 124.6 
rs12727642 1 7.2 rs6806528 3 69.3 rs1250552 10 75.1 
rs426561* 1 7.2 rs11712165 3 116.5 rs11221332 11 124.3 
rs10903122 1 23.6 rs17810546 3 157.1 rs653178 12 109.0 
rs6691768 1 59.9 rs10936599 3 166.9 rs2762051 13 31.6 
rs864537 1 138.7 rs1464510 3 185.5 rs4899260 14 49.4 
rs859637 1 143.9 rs13151961 4 118.8 rs12928822 16 11.3 
rs2816316 1 163.8 rs13119723* 4 118.9 rs2074404 17 40.2 
rs296547 1 172.1 rs13109373* 4 158.8 rs1893217 18 12.8 
rs13003464 2 60.9 rs1033180 6 0.3 rs601338 19 48.4 
rs17035378 2 68.3 rs10806425 6 88.1 rs242372* 21 14.3 
rs917997 2 96.8 rs802734 6 125.9 rs4819388 21 31.0 
rs13010713 2 173.9 rs2327832¤ 6 135.5 rs2298428 22 4.9 
rs4675374 2 196.6 rs9295089* 6 156.9 rs5979785 X 10.7 
rs4675377* 2 196.7 rs1738074 6 156.9 
  
  
rs13314993 3 33.0 rs6974491 7 37.3     
The SNP positions are based on Genome build 37.1 HuRef. The SNP in bold text was used in Study II and all other SNPs 
were used in Study III. *SNP not from the CelD GWAS, ¤: SNP genotyped by Taqman. 
 
Table 8. The number of subjects (identified by group) in Study II and Study III 
are tabulated. 
 
Study II Study III 
Group Cohort_FIN Cohort_FIN Cohort_SWE 
Controls 2738 2482 341 
CelD 943 
 
  
DH 119 
 
  
CelD + DH 1025 
 
  
CD 303 240   
UC 545 459 923 
IBD 745 699   
Study II: rs601338-FUT2 association study; Study III: Shared CelD-IBD genes; 
Cohort_FIN: Finnish study subjects; Cohort_SWE: Swedish study subjects 
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Patient and control samples from Finland and Sweden were included in Study III (Table 8). In the 
Finnish dataset, there were 699 unrelated IBD patients. Of these, 240 patients had CD and 459 
patients had UC. There were 2482 healthy controls in study III derived from the FINRISK and Health 
2000 cohorts (FINRISK , Health 2000 ), already genotyped in the CelD GWAS (Dubois et al. 2010) for 
the studied markers. The IBD patients in both studies (Study II and Study III) were recruited at the 
Helsinki University Hospital and Maria Hospital and also at University Hospitals in Turku, Tampere, 
Kuopio and Oulu. The diagnostic criteria and methods of clinical assessment of these patients have 
been described previously (Helio et al. 2003, Halme et al. 2002). The Swedish sample collection 
consisted of 923 UC cases and 341 healthy controls and has been described in detail in a previous 
study (McGovern et al. 2010a). To study the association of CelD risk genes with different CD and UC 
subphenotypes (Table 9), all the patients were divided into groups based on the clinical presentation 
of their disease. For every subphenotype that was studied, the patients were regrouped accordingly, 
thus it was possible for one patient to be present in different groups. In brief, the CD patients were 
divided into 16 groups and the UC patients were divided into six groups. These groups are 
summarized in Table 9. 
9. Genotyping 
The FUT2 SNP marker rs601338 was genotyped in 1045 controls, 943 CelD patients, 119 DH patients, 
303 CD patients and 545 UC patients using TaqMan chemistry (Life technologies, Carlsbad, CA, USA) 
with a forward primer (GGGAGTACGTCCGCTTCAC), a reverse primer (TGGCGGAGGTGGTGGTA), 
reporter 1-VIC (CTGCTCCTAGACCTT) and reporter 2-FAM (CTGCTCCTGGACCTT). All the patient 
samples were genotyped in house using ABI 7900HT real-time PCR system. The blood donor control 
samples (N=1045) had been earlier genotyped at an external facility (Technology Centre, Institute for 
Molecular Medicine Finland, University of Helsinki, Helsinki, Finland) using the same TaqMan 
primers and probes and a LightCycler 480 Real-Time PCR Instrument (Roche, Basel, Switzerland). The 
software version 1.5 (endpoint genotyping analysis) was used to call the genotypes for control 
samples, and the success rate was 100%. The genotyping was successful for 879 of 943 CelD 
patients, 116 of 119 DH patients, 280 of 303 CD patients and 496 of 505 UC patients giving a success 
rate of 93%, 97.5%, 92.4% and 91% respectively. The genotyping success rate for all the cases 
together was 92.8%. The genome-wide data from previous GWAS (Dubois et al. 2010) (Illumina 610-
Quad platform) was used to impute genotypes for 1693 control subjects using the IMPUTE2 program 
(Howie, Donnelly & Marchini 2009). For genotype imputations, the 1000 genomes phase I interim 
build (June 2011) was used as reference (1000 Genomes Project Consortium 2010) and only 
genotypes with a quality score ≥ 0.95 were used in the analyses. To check the reliability of this 
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method, genotypes for 609 of 943 directly genotyped CelD patients were obtained by imputing. The 
concordance rate between the two methods was 97.7%. For 30 CelD patient samples, also previously 
genotyped genome wide, direct genotyping by Taqman chemistry had failed, hence their imputed 
genotypes were used in the analysis. Thus, genotypes for 909 (879 + 30) CelD patients were available 
for the analysis. The distribution of genotypes in control datasets did not deviate significantly from 
Hardy-Weinberg equilibrium (P > 0.05). 
 
  
Table 9. The subphenotypes of CD and UC patients along with the number of affected 
individuals in each group are given below. 
Patient subphenotype Cohort_FIN Cohort_SWE 
Crohn's disease n = 240   
Onset age: 0-18 yrs 34   
Onset age:19 yrs and above 196   
Familial CD 41   
Sporadic CD 189   
Left or Right colitis 57   
Extensive colitis 113   
Terminal ileits (L1) 54   
Affected colon (L2) 55   
Ileocolonic disease (L3) 112   
Perianal fistula 37   
No Perianal fistula 193   
Stricturing phenotype 86   
Penetrating and Fistulising phenotype 53   
Non-stricturing Non-penetrating phenotype 91   
Mutations in NOD2 37   
No mutations in NOD2 196   
Ulcerative colitis n = 459 n = 923 
Onset age: 0-18yrs 59 61 
Onset age:19 yrs and above 382   
Familial UC 115 51 
Sporadic UC 326 483 
Left-sided colitis 166   
Extensive colitis 275   
Cohort_FIN: Finnish study subjects; Cohort_SWE: Swedish study subjects. L1, L2 and L3 are 
depicted in Figure 3. 
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In Study III, the Finnish IBD cases were genotyped using the matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) analysis on a Massarray Analyzer platform 
(Sequenom, San Diego, CA, USA) at the Finnish Genome Center, FIMM, Helsinki, Finland. The Finnish 
control samples were genotyped using the Illumina 610-Quad platform as described previously 
(Dubois et al. 2010). Due to multiplexing incompatibility of one marker (rs2327832), it was 
genotyped using Taqman chemistry (Applied Biosystems, Foster city, CA, USA) in the Finnish IBD 
dataset. The genotyping success rate for this marker was 97.3%. In both cases and controls, the 
overall genotyping success rate for all the markers was between 98.2% and 99.9%. To confirm that 
all three genotyping platforms (Sequenom-MALDI-TOF, Illumina 610-Quad and Taqman chemistry) 
were consistent, some control samples were genotyped on all three platforms. No discrepancy in 
genotyping was found among different methods. 
The Swedish UC samples and control samples were genotyped on an Illumina Hap550 array and 
Illumina Quad-610 Beadchips. Detailed information on samples, genotyping quality control and 
genotyping call rates has been provided elsewhere (McGovern et al. 2010a). 
10. Power calculations  
The genetic power calculator (http://pngu.mgh.harvard.edu/∼purcell/gpc/cc2.html) (Purcell, Cherny & 
Sham 2003), using the case-control for discrete traits option, was used to calculate the power of our 
datasets to detect associations. In Study II (rs601338-AA (FUT2) association study), the prevalence of 
CelD and IBD was set to 0.01 and 0.004 respectively. The frequency of rs601338-A allele was set to 
0.412 as suggested previously (McGovern et al. 2010b). For the odds ratios (ORs) 1.15-1.5, the CelD, 
DH and CelD + DH datasets gave 29%-99%, 9%-44% and 32%-100% power respectively. For the same 
ORs, the UC, CD and UC + CD datasets gave 20%-93%, 14%-77% and 26%-98% power, respectively.  
In the Study III, three different allele frequencies (0.20, 0.25 and 0.30) were used to calculate the 
power of our study to detect association. These allele frequencies were representative of the minor 
allele frequencies of the CelD risk variants identified by Dubois et al. in CelD GWAS (Dubois et al. 
2010). The range of ORs used for power calculations was 1.15-1.4. In the Finnish CD and UC datasets, 
the power to detect an association, for the mentioned ORs and allele frequencies, ranged from 18% 
to 57% and from 27% to 81% respectively. The power in the Swedish-Finnish UC meta-analysis was 
estimated to be between 55% and 99%.    
11. Data analysis 
For association analyses, the genotypes and affection status were imported to the BC-SNPmax LIMS 
database (Biocomputing platforms, Espoo, Finland) and single marker association tests and, where 
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relevant, two marker haplotype association tests, were performed using PLINK version v1.07 (Purcell 
et al. 2007). In Study III, a meta-analysis of Swedish-Finnish UC datasets was performed using the 
Cochran-Mantel-Haenszel function in PLINK. To check for homogeneity of ORs, the combined 
datasets were subjected to Breslow-Day test. No marker deviated significantly from homogeneity (P 
< 0.05). In the association analyses (Study II and Study III) statistical threshold for a significant 
association was set at P < 0.05. When multiple SNP markers are used in an analysis, the obtained P-
values for association must be corrected for multiple testing (e.g.  using Bonferroni correction for 
multiple testing). This may prove problematic in analyses where an association with a SNP has been 
detected using a small sample size. Multiple testing correction in such cases usually results in a loss 
of statistical significance (i.e. P > 0.05). Several subgroups in study III have a small sample size. In 
Study III, P values uncorrected for multiple testing have been reported throughout. However, in each 
association analysis, the option to perform 10 000 permutations was selected. This method was used 
as a less stringent alternative to Bonferroni correction for multiple testing. This method generates an 
empirical P value (PEMP2) for each association and PEMP2 < 0.05 is considered statistically significant. 
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Results 
1. Study I: The effect of gliadin peptides on Caco-2 cell gene transcription 
The effect that the gliadin peptides have on Caco-2 cell gene transcription was studied using 
microarray chips and qRT-PCR method. The results of these analyses are outlined below. 
1.1. Differential gene expression in Caco-2 cells after gliadin treatment 
The genes on the microarrays utilized in this study are represented by probes and several genes are 
represented by more than one probe. Hence, the number of differentially expressed probes does 
not correspond to the number of differentially expressed genes. For this reason, the term probe, 
instead of gene, is used. A complete list of probes, which were differentially regulated (uncorrected 
P < 0.01) accompanies Publication I. A visual presentation of the data is provided in Figure 6. After 
six hours treatment with PT-G, the expression of 1705 probes was affected in Caco-2 cells compared 
to the expression in cells that were kept in medium only (MED-CTL). In contrast, 1755 probes were 
differentially expressed after PT treatment. The expression of 1145 probes was affected by both PT-
G and PT treatment. A statistically significant (uncorrected P < 0.05) change in the expression of 211 
probes was observed in Caco-2 cells treated with the synthetic p31-43 peptide. Out of these 211 
probes, 21 probes were common between PT treatment and p31-43 treatment, whereas PT-G 
treatment shared ten probes with p31-43 treatment. The expression of 46 probes was affected by all 
three treatments compared to MED-CTL, whereas the expression of 543, 504 and 134 probes was 
unique to PT, PT-G and p31-43 treatments respectively. 
1.2. Validation of differentially expressed genes by qRT-PCR 
The observed changes in the expression of probes by different treatments were verified by qRT-PCR. 
Four probes corresponding to four different genes were selected based on the criteria described in 
the materials and methods section. Fold change (FC) values greater than one indicate up-regulation 
and smaller than one indicate down-regulation. In total, the expression of five genes was verified by 
qRT-PCR. The expression of three genes [CCAAT/enhancer binding protein alpha (CEBPa), Kruppel-
like factor 4 (KLF4) and sprouty-related, EVH1 domain containing 1 (SPRED1)] was affected by PT-G 
treatment. Two genes [mitochondrial nucleoid factor 1 (MNF1) and RELA] were affected by p31-43 
treatment. The qRT-PCR results for these genes are shown in Table 10. 
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Figure 6. The probes affected by PT, PT-G and p31-43 treatment are shown. PT: pepsin and trypsin blank control; PT-G: 
pepsin and trypsin digested gliadin; MED-CTL: medium only control. 
The qRT-PCR analysis verified the change in gene expression levels observed in the microarrays for 
the genes CEBPa, KLF4 and SPRED1. The CEBPa gene was down-regulated to a similar degree in qRT-
PCR as on the microarrays (0.66 vs. 0.71) and the level of up-regulation for KLF4 (1.78 vs. 2.0) and 
SPRED1 (1.50 vs. 1.66) was also comparable. For all three genes the expression levels were affected 
to a similar degree by negative controls, i.e. PT, PT-BSA and PT-L (Table 10). In contrast, for the p31-
43 peptide affected genes, the microarray results could not be validated. The expression values in 
qRT-PCR for the MNF1 and RELA genes were more similar to MED-CTL and the negative control p57-
68 treated cells. 
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2. Study II: Association of FUT2 with CelD, DH and IBD in the Finnish population 
The genotype distribution in CelD (P= 0.0006) and CelD + DH (P= 0.0004) datasets deviated 
significantly from HWE. Although the DH, UC and CD datasets were in HWE (P > 0.05), the deviation 
from HWE in the UC + CD dataset was statistically significant (P = 0.034). The AA genotype of the 
rs601338 SNP marker, which is associated with FUT2 non-secretor status, showed significant 
genotype association with increased risk for CelD [P= 0.0074, OR: 1.28 (95% CI 1.05-1.56)] in the 
Finnish population (Table 11). In addition, rs601338-A also showed a nominal, but statistically 
significant, recessive association [P= 0.015, OR: 1.28(1.05-1.56)]. The rs601338 SNP did not associate 
with DH subset of CelD patients under any of the tested association models (P > 0.05). Interestingly, 
when the association of rs601338-AA genotype was tested in the combined CelD + DH dataset, an 
association pattern similar to the CelD dataset alone was observed. Rs601338 showed significant 
genotype association of the non-secretor FUT2 genotype (rs601338-AA) in the CelD + DH datasets 
[P= 0.0060, OR: 1.28 (1.06-1.55)] and rs601338-A showed recessive association with disease risk in 
the CelD + DH dataset [P= 0.011, OR: 1.28 (1.06-1.55)]. There were approximately 18.0% non-
secretors in all three patient groups, CelD, DH and CelD + DH, compared to 14.7% in control 
individuals.  
  
Table 10. Validation of microarray results for selected genes by qRT-PCR. 
qRT-PCR Microarray 
Gene MED-CTL PT PT-BSA PT-L PT-G p57-68 p31-43 PT-G p31-43 
CEBPa 1.01 0.80 0.73 0.66 0.66 
  
0.71   
KLF4 1.06 1.71 1.91 1.72 1.78 
  
2.0   
SPRED1 1.04 1.48 1.38 1.16 1.50 
  
1.66   
MNF1 1.00 
    
0.93 0.84 
 
1.91 
RELA 1.05     0.99 1.05  1.31 
The qRT-PCR results for CCAAT/enhancer binding protein alpha (CEBPa), Kruppel-like factor 4 (KLF4), SPRED1: Sprouty-
related, EVH1 domain containing 1 (SPRED1) are based on eight independent experiments. The qRT-PCR results for 
Mitochondrial nucleoid factor 1 (MNF1), REL-A: v-rel reticuloendotheliosis viral oncogene homolog A (REL-A), are based on 
five independent experiments. The expression of genes was normalised against Beta-2 microglobulin (B2M) gene. The 
values expressed for different treatments are the average expression values. 
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3.1. Association of CelD risk loci with CD and/or UC in the Finnish population 
The SNPs which were significantly associated with CD and UC (uncorrected P < 0.05) are listed in 
Table 12 and Table 13 respectively. Six SNPs each were associated with CD and UC and two SNPs 
(rs1893217-PTPN2 and rs4819388-ICOSLG) were associated with both forms of IBD. Of the 
associated SNPs, the strongest association with CD was observed for SNP rs4819388-ICOSLG [P= 
0.015, OR: 1.35 (1.06-1.71)] with the over-representation of the G risk allele in CD patients 
compared to healthy controls (81% vs. 76%). The strongest evidence for association with UC was for 
SNP rs242372-A [P= 0.0076, OR: 1.33 (1.08-1.64)]. In addition, seven CelD risk alleles were protective 
(OR < 0.90) against CD or UC and 23 risk alleles were associated with higher risk (OR > 1.10) for CD or 
UC (Publication III, Table 1).  However, when the P-values were corrected for the number of markers 
tested, as described in the materials and methods section, the observed associations were no longer 
statistically significant (PEMP2 > 0.05). The association of two or three marker haplotypes with CD 
and/or UC was also studied, but no significant associations were found. 
Table 12. CelD risk loci with significant association with CD are shown. 
           CTL CD 
Marker Chr Mb Candidate genes R_A RAF RAF P OR 
rs12727642 1 7.2 PARK7, TNFRSF9 T 0.26 0.21 0.020 0.76 
rs10936599 3 166.9 MYNN A 0.26 0.31 0.010 1.31 
rs13109373 4 158.8 FSTL4 T 0.12 0.16 0.031 1.34 
rs653178 12 109.0 SH2B3, ATXN2 C 0.41 0.46 0.039 1.22 
rs1893217 18 12.8 PTPN2 C 0.16 0.20 0.047 1.28 
rs4819388 21 31.0 ICOSLG G 0.76 0.81 0.015 1.35 
45 SNPs were tested for their association with CD (n = 230) and 2482 controls were used in each analysis. The 
uncorrected P-values < 0.05 are given. The SNP positions are based on Genome build 37.1 HuRef. Mb: Genomic 
location in mega bases, R_A: Risk allele as in Dubois et al., CTL: Controls, RAF: Risk allele frequency. 
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Table 13. CelD risk loci with significant association with ulcerative colitis are shown. 
           CTL UC 
Marker Chr Mb Candidate genes R_A RAF RAF P OR 
rs864537 1 138.7 CD247 T 0.70 0.26 0.017 1.22 
rs13119723 4 118.9 IL2, IL21, ADAD1 G 0.10 0.12 0.040 1.26 
rs11221332 11 124.3 ETS1 A 0.23 0.26 0.036 1.19 
rs1893217 18 12.8 PTPN2 C 0.16 0.19 0.033 1.22 
rs242372 21 14.3 
 
A 0.12 0.15 0.0076 1.33 
rs4819388 21 31.0 ICOSLG G 0.76 0.20 0.016 1.24 
45 SNPs were tested for their association with UC (n = 441) and 2482 controls were used in each analysis. The 
uncorrected P-values < 0.05 are given. The SNP positions are based on Genome build 37.1 HuRef. Mb: Genomic 
location in mega bases, R_A: Risk allele as in Dubois et al., CTL: Controls, RAF: Risk allele frequency. 
3.2. Association of CelD risk loci with subphenotypes of CD and/or UC in the Finnish population 
The association of CelD risk alleles with different subphenotypes of CD and UC was also investigated 
and the complete results are shown in publication III, Table 2. In total, 28 SNPs were associated 
(uncorrected P < 0.05) with CD and/or UC. Of these associations, 22 associations were specific for a 
CD subphenotype, 17 associations were UC subphenotype specific and 11 SNPs were associated with 
both CD and UC subphenotypes. The SNP rs6974491-A-ELMO1 showed strong evidence for 
association with early-onset UC [uncorrected P =0.0002, OR: 2.20 (1.44-3.36)]. The risk allele was 
present in 26% of UC patients (n=59, UC onset age: 0-18 years) but only in 14% of healthy controls. 
Similarly, rs2298428-T-UBE2L3 was associated with early-onset CD [uncorrected P= 5.4x10-4, OR: 
2.59 (1.61-4.19)] and the risk allele was overrepresented in CD patients compared to healthy 
controls (50% vs. 29%). This SNP was also associated with the non-stricturing, non-penetrating 
phenotype of CD [uncorrected P =0.0010, OR: 1.66 (1.22-2.25)]. All three associations remained 
statistically significant (PEMP2 < 0.05) after correcting for the multiple tests performed in the analysis.  
3.3. Meta-analysis of Finnish and Swedish UC datasets 
The results of the Finnish and Swedish UC meta-analysis are shown in Table 14. However, only those 
SNPs which were significantly associated (uncorrected P < 0.05) in either dataset (i.e. Finnish, 
Swedish or the combined Finnish + Swedish) are presented in the table. Seven SNPs were 
significantly associated with UC and three SNPs remained significantly associated (PEMP2 < 0.05) after 
correcting for the number of markers in the analysis. Two of these markers rs13003464-G-PUS10 
[uncorrected P=0.0010, OR: 1.22 (1.08-1.37)] and rs4819388-G-ICOSLG [uncorrected P=0.00042, OR: 
1.27 (1.11-1.45)] were associated with increased risk for UC, whereas one marker rs1738074-A-
TAGAP [uncorrected P=0.0.0012, OR: 0.83 (0.73-0.93)] was protective.  
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The results from the Finnish-Swedish UC subphenotype meta-analysis are shown in Table 15. In total, 
nine SNP markers were associated (uncorrected P < 0.05) with one or more UC subphenotypes. The 
most significant findings in this analysis were strong associations with familial UC, sporadic UC and 
early-onset UC (onset age: 0-18 years). rs1738074-A-TAGAP was associated with familial UC 
[uncorrected P=7.40 x 10-5, OR: 0.61 (0.47-0.77) and PEMP2 < 0.005]. The associated allele showed a 
protective effect, being present in 43% of the controls but only in 33% of the affected individuals 
with a family history of UC. The SNP which showed strong evidence for association with sporadic UC 
was rs4819388-G-ICOSLG [uncorrected P=0.00019, OR: 0.75 (0.65-0.87) and PEMP2 < 0.005]. The CelD 
risk SNP rs6974491-A-ELMO1 was associated with early-onset UC [uncorrected P=0.00052, OR: 1.73 
(1.26-2.37) and PEMP2 < 0.05]. 
Table 14. Meta-analysis of Finnish and Swedish UC datasets. 
Marker R_A Candidate genes 
FIN_UC  
(n= 441) 
SWE_UC 
(n=923) 
UC meta-analysis 
(n=1368) 
rs12727642 A PARK7, TNFRSF9 0.14 (0.88) 0.17 (0.86) 0.034 (0.87) 
rs10903122 G RUNX3 0.17 (0.90) 0.038 (0.83) 0.030 (0.88) 
rs864537 T CD247 0.017 (1.22) 0.11 (1.16) 0.0046 (1.19) 
rs13003464 G PUS10 0.064 (1.15) 0.015 (1.25) 0.0010* (1.22) 
rs13119723 G IL2, IL21 0.040 (1.26) 0.47 (0.91) 0.33 (1.09) 
rs10806425 A BACH2 0.47 (1.06) 0.014 (0.80) 0.11 (0.91) 
rs1738074 A TAGAP 0.059 (0.87) 0.021 (0.81) 0.0012* (0.83) 
rs653178 G SH2B3, ATXN2 0.066 (1.15) 0.082 (1.17) 0.016 (1.15) 
rs1893217 G PTPN2 0.033 (1.22) 0.21 (0.87) 0.43 (1.06) 
rs2423721 A 
 
0.0076 (1.33) 0.19 (0.85) 0.20 (1.11) 
rs4819388 G ICOSLG 0.016 (1.24) 0.0086 (1.30) 0.00042* (1.27) 
The number of controls in the Finnish- and Swedish- UC meta-analysis was 2482 and 341 respectively. The SNPs and P-
values showing more significant association in the UC meta-analysis compared to the individual analysis (FIN_UC and/or 
SWE_UC) are underlined. The associations which remained significant after multiple testing correction are marked with 
asterisk (*) (*PEMP2<0.05) 
1
Genotypes for only 2171 controls were available. R_A: Risk allele as in Dubois et al.  
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Table 15. UC-subphenotype meta-analysis of Finnish- and Swedish UC datasets. 
Marker R_A 
Candidate 
genes 
FAMILIAL UC SPORADIC UC UC ONSET AGE: 0-18yrs 
FIN 
(n=115) 
SWE 
(n=51) 
FIN+SWE 
(n= 166) 
FIN 
(n=326) 
SWE 
(n=483) 
FIN+SWE 
(n= 813) 
FIN 
(n=59) 
SWE 
(n=61) 
FIN+SWE 
(n= 120) 
rs10903122 G RUNX3       
0.17 
(0.89) 
0.087 
(0.84) 
0.029 
(0.87)       
rs864537 T CD247       
0.015 
(1.26) 
0.064 
(1.21) 
0.0022 
(1.24) 
0.018 
(1.73) 
0.43 
(1.18) 
0.019 
(1.44) 
rs859637 A 
FASLG, 
TNFSF18 
0.070 
(0.78) 
0.20 
(0.76) 
0.03      
(0.77)             
rs2816316 A RGS1             
0.096 
(0.68) 
0.20 
(0.73) 
0.043 
(0.71) 
rs13003464 G PUS10       
0.076 
(1.16) 
0.038 
(1.24) 
0.0021 
(1.23)       
rs917997 A 
IL18RAP, 
IL18R1 
0.88 
(1.03) 
0.043 
(0.57) 
0.17       
(0.81)             
rs10936599 A MYNN             
0.16 
(1.32) 
0.10 
(1.43) 
0.029 
(1.38) 
rs10806425 A BACH2       
0.09 
(1.17) 
0.0043 
(0.75) 
0.19  
(0.91)       
rs1738074 T TAGAP 
0.0012 
(0.63) 
0.039 
(0.64) 
0.000074** 
(0.61) 
0.70 
(0.97) 
0.021 
(0.79) 
0.034 
(0.87)       
rs6974491 A ELMO1             
0.00020 
(2.20) 
0.26 
(1.30) 
0.00052* 
(1.73) 
rs2762051 A   
0.094 
(1.30) 
0.024 
(0.50) 
0.86      
(1.03)             
rs4819388 G ICOSLG       
0.0022 
(1.38) 
0.021 
(1.29) 
0.00019** 
(1.33)       
The number of controls in the FIN+SWE UC subphenotype meta-analysis was 2823. The associations which remained significant after multiple testing 
correction are marked with asterisk (*) (* PEMP2<0.05 and ** PEMP2<0.005). R_A: Risk allele as in Dubois et al.  
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Discussion 
The main purpose of this study was to explore the shared genetic background in CelD and IBD and 
investigate the impact and interplay of selected genes and environmental factors on CelD and IBD 
susceptibility. In CelD, gluten peptides are the disease causing environmental triggers and critical 
epitopes for T-cell driven pathogenesis. However, a complete picture of how (and if) gluten affects 
epithelial cell gene transcription remains elusive (i.e. environmental effects on genes). The gut 
microbiota is known to affect the development of the innate and adaptive immune system and 
polymorphisms in the FUT2 gene have been shown to affect the composition of gut microbiota 
(genetic influence on environment). Inflammation in chronic inflammatory diseases (such as CelD 
and IBD) is sustained by effector cells of the immune system.  Inflammation is the end product of an 
intricate signaling cascade which is affected by changes in the transcription and/or translation 
pattern of multiple genes. Clinically distinct inflammatory diseases are likely to share underlying 
disease risk due to similar changes in some of these genes. 
1. Modest effect of gliadin peptides and novel, non-enzymatic effects of pepsin and trypsin on Caco-2 
gene transcription   
The effects of gliadin peptides on epithelial cell gene transcription were investigated using gene 
expression microarrays and select genes from this assay were verified using qRT-PCR. The qRT-PCR 
assay validated that the expression of three genes, CEBPa, KLF4 and SPRED1 is indeed affected by 
PT-G. However, these effects are unlikely to be direct effects of gliadin peptides as similar changes in 
gene expression (with respect to direction and magnitude) were also brought about by the negative 
controls PT, PT-BSA and PT-L. Furthermore, the expression values of genes affected by the cytotoxic 
p31-43 peptide were similar to those of the control, suggesting that these genes may be false 
positives. As compared to the MED-CTL, after exposure to PT-G a unique set of 504 probes was 
differentially expressed in Caco-2 cells and only three genes were verified by qRT-PCR. It is practically 
unrealistic to replicate all the affected genes by qRT-PCR. Thus it cannot be concluded that gliadin 
peptides have no effect on enterocyte gene expression. The possible conclusions that can be drawn 
from the data are as follows: the direct effects of gliadin derived peptides on epithelial cell gene 
transcription are marginal; pepsin- and trypsin- derived peptides are able to affect enterocyte gene 
expression and the effect of the gliadin peptides on enterocytes requires the presence of other 
components of the immune system (i.e. effector cells and/or cytokines) or mucosal environment. 
Several previous studies (Table 16) have attempted to identify genes that are differentially regulated 
in CelD (Diosdado et al. 2004, Juuti-Uusitalo et al. 2004, Simula et al. 2010, Bracken et al. 2008). This 
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study is not directly comparable to those studies as they have been performed on biopsy samples 
obtained from CelD patients or on enterocytes isolated from CelD biopsies. Although no gene 
expression microarray study investigating the effects of gliadin peptides on cultured epithelial cells 
has been performed, many comparisons can be made between this study and previous microarray 
studies.  
Juuti-Uusitalo et al. compared gene expression in duodenal biopsies from untreated- and treated- 
CelD patients with that of healthy controls (Juuti-Uusitalo et al. 2004). There were 156 and 60 genes 
differentially regulated in untreated and treated groups respectively compared to controls. Ninety-
eight genes were differentially regulated between the untreated and treated groups. Nine 
differentially expressed genes reported by Juuti-Uusitalo et al. were also among the differentially 
regulated genes in this study (Table 16). However, three of the nine genes were affected by both PT 
and PT-G in our study and two genes were affected by PT only. The RALY (RNA-binding protein, 
autoantigenic) gene was up-regulated in Caco-2 cells exposed to p31-43 peptide and was also over-
expressed in treated CelD biopsy samples. The function of RALY gene is however poorly understood. 
The genes, CD59 antigen (CD59), Ephrin B2 (EFNB2) and Myosin VI (MYO6) genes were affected by 
PT-G. The difference in FC was almost identical for RALY, EFNB2 and MYO6 between the two studies 
and all were up-regulated. It is of note that FC for these genes in both studies are modest (i.e. FC ≤ 
1.60). The CD59 gene was 1.5 fold down-regulated in the study by Juuti-Uusitalo et al. whereas it 
was 1.4 fold up-regulated in our study. The CD59 gene encodes a glycosylphosphatidylinositol (GPI)-
linked protein which is the cell surface inhibitor of the membrane attach complex on human cells 
(Piccoli et al. 2011). The CD59 protein is expressed in most tissues and in all circulating cells, 
including erythrocytes and leukocytes. Interestingly, the expression of CD59 on cell surface also 
makes the cells more susceptible to NK cell-mediated cytotoxicity (Marcenaro et al. 2003, Omidvar 
et al. 2006) and genetic variants within this gene have been linked to CelD in a previous study (Vidal 
et al. 2009). It is possible that under physiological conditions (e.g. biopsy samples), the CD59 gene 
expression is affected by other factors (other cells, cytokines etc.) also which are absent in vitro 
assays (cultured cells). This is likely to be the reason for differential expression pattern of this gene 
between the two studies.  The EFNB2 gene was over-expressed in both untreated CelD biopsies and 
Caco-2 cells stimulated with PT-G. This gene is important in T cell development and immune 
regulation (Yu et al. 2003, Luo et al. 2011). Similarly, MYO6 gene was over-expressed in both studies 
and has been reported to facilitate the translocation of endocytic vesicles from cell peripheries 
(Aschenbrenner, Lee & Hasson 2003).  
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In another study (Diosdado et al. 2004), the differences in gene expression were studied in biopsy 
specimens obtained from CelD patients on a GFD and CelD patients on a gluten containing diet. Four 
genes affected by PT and PT-G in this study were reported to be differentially expressed. Bracken et 
al. examined the gene expression profile of intestinal epithelial cells using microarrays (Bracken et al. 
2008). However, the difference between our study and the one by Bracken et al. is that the epithelial 
cells in the latter study were isolated from biopsy specimens from CelD patients with active disease 
and from control subjects. In addition, the isolated enterocytes were not exposed to PT-G. As shown 
in Table 16 two genes, ETS-domain protein (ELK4) which is also known as SRF accessory protein 1 
(SAP1) and prion protein (PRNP), were affected by PT-G only in this study. The ELK4 gene was 
approx. 1.4 fold up-regulated in both studies whereas the PRNP gene was 1.3 fold up-regulated in 
our study and approximately two fold down-regulated in the other study. The ELK4 gene is required 
for thymocyte positive selection (Costello et al. 2004) whereas the PRNP gene is over-expressed in 
response to endoplasmic reticulum (ER) stress and delays ER stress-induced cell death. The fact that 
these genes were affected by PT-G only (and not PT), and given their role in T cell development, 
immune regulation, apoptosis and endocytic vesicle translocation, further studies are warranted to 
ascertain their role in CelD pathogenesis. 
Pepsin and trypsin are proteolytic enzymes with different substrate specificities which participate in 
the digestion of food by breaking down food protein into peptides. Interestingly, in addition to their 
role in food digestion, effects unrelated to the digestive process have been reported.  Pepsin is 
released as a pro-form zymogen, pepsinogen, by chief cells in the stomach. Upon activation under 
acidic conditions in the stomach, pepsinogen cleaves itself in an autocatalytic fashion to make 
pepsin. Pepsin displays maximum activity at pH 2.0 and is inactive at pH 6.5 or higher, however it 
remains stable until pH 8.0 and can be reactivated by lowering the pH.(Johnston et al. 2007). 
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Table 16. Comparison of microarray data with previous studies 
    
Microarrays Previous studies 
Gene PT-G PT p31-43 
Juuti-
Uusitalo et 
al. 2004 
Diosdado et 
al. 2008 
Bracken et 
al. 2008 
Condition 
DLX4 1.60 1.50   1.95 
  
UCD vs. HC 
DLX4 1.60 1.50   1.42 
  
UCD vs. TCD 
DLX4 1.60 1.50   1.37 
  
TCD vs. HC 
JUNB 3.40 2.90   0.75 
  
UCD vs. HC 
NAB2 2.00 1.90   0.54 
  
UCD vs. HC 
PROCR 
 
1.40   1.43 
  
TCD vs. HC 
SLC25A6 
 
1.80 1.70 1.40 
  
UCD vs. HC 
SLC25A6 
 
1.80 1.70 1.45 
  
UCD vs. TCD 
RALY 
  
1.60 1.43 
  
TCD vs. HC 
CD59 1.40 
 
  0.66 
  
UCD vs. HC 
EFNB2 1.40 
 
  1.41 
  
UCD vs. TCD 
MYO6 1.27 
 
  1.27 
  
TCD vs. HC 
HSPA6 2.60 2.90     1.32 
 
MIII-G+/G-a 
MSI2 0.75 0.72     0.78 
 
MIII-G+/G-a 
POLD3 0.66 0.61     0.63 
 
MIII-G+/G-a 
RGS16 2.70 2.57     0.81 
 
MIII-G+/G-a 
ELK4 1.37 
 
    
 
1.45 Ent. CD vs. Ent. HC 
UBE3A 
 
0.82     
 
0.77 Ent. CD vs. Ent. HC 
NUDT2 0.72 0.74     
 
2.21 Ent. CD vs. Ent. HC 
PRNP 1.31        0.54 Ent. CD vs. Ent. HC 
Expression values > 1 indicate up-regulation and < 1 indicate down-regulation. Condition refers to the experimental condition 
used in the original study. UCD: Biopsy from untreated CD, TCD: Biopsy from treated CD, HC: Biopsy from healthy control, MIII-
G+: Biopsy from Marsh-III stage CD patient on gluten containing diet, MIII-G-: Biopsy from Marsh-III stage CD patient on 
gluten-free diet, Ent. CD: Epithelial cells isolated form duodenal biopsies of CD patients, Ent. HC: Epithelial cells isolated from 
duodenal biopsies of healthy controls. 
a
In the original study, the expression values were given for MIII-G-/G+ and comparable 
values for MIII-G+/G- were obtained (1/MIII-G-/G+) in the study. 
 
Bathoorn et al. reported  that, in a pH- and concentration- dependent manner, pepsin has cytotoxic 
effects on bronchial epithelial cells and also promotes inflammation by inducing the production of 
inflammatory cytokines (IL-8 and IL-6) (Bathoorn et al. 2011). These effects were more pronounced 
at lower pH (at pH 1.5 compared to pH 2.5). Furthermore, the effect of pepsin (at pH 7.0) on normal 
human laryngeal primary epithelial cells and hypopharyngeal FaDu squamous cell carcinoma (SCC) 
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cells has also been studied (Johnston et al. 2012). It was reported that the expression of 27 genes in 
FaDu cells and 31 genes in laryngeal primary epithelial cells is differentially regulated after exposure 
to pepsin at neutral pH. The treatment with pepsin also promoted proliferation in these cells. 
Trypsin is a serine protease which is produced in the pancreas as an inactive zymogen, trypsinogen. 
It is secreted via the pancreatic duct in the duodenum where it is cleaved and activated under non-
acidic conditions (pH-7.5-8.0) by enteropeptidase (Kunitz 1939). Trypsin is a natural activator of 
proteinase-activated receptor-2 (PAR2) which belongs to a family of G protein-coupled receptors 
(GPCRs). In the GI, PAR2 is involved in the regulation of exocrine secretion, modulation of smooth 
muscle motility and plays an important role in mucosal inflammation throughout the GI (Kawabata, 
Matsunami & Sekiguchi 2008, Tanaka et al. 2008). Furthermore, a study in mice showed that trypsin 
inhibited lipopolysaccharide (LPS) signaling by degrading TLR4 accessory molecules independent of 
PAR2 activation (Komatsu et al. 2012). In a microarray study, the effect of PAR2 activation by trypsin 
on human embryonic kidney 293 (HEK293) cell gene expression was investigated (Suen et al. 2010). 
The expression of several genes involved in cellular metabolism, cell cycle, inflammation and the 
mitogen-activated protein kinase (MAPK) pathway was affected. Among the genes affected by 
pepsin and trypsin treatments in these studies (Johnston et al. 2012, Suen et al. 2010) five pepsin-
affected genes and 16 trypsin-affected genes were also differentially expressed in this study (Table 
17). For all, but two trypsin-affected genes, these changes were in the same direction and of 
comparable magnitude. Of the five pepsin-affected genes, one gene (BRCA1) was down-regulated in 
both studies, one gene (ETS2) was up-regulated in FaDu and Caco-2 cell, but not in primary epithelial 
cells. The remaining three genes were down-regulated in the previous study but up-regulated in this 
study. The difference in the direction of change for some genes in the studies may depend upon 
different origin of the cells being compared. Nonetheless, it is interesting that trypsin affects gene 
transcription.  
Taken together, data from our study, the three CelD studies (Diosdado et al. 2004, Juuti-Uusitalo et 
al. 2004, Bracken et al. 2008) and the gene expression studies using pepsin and trypsin (Johnston et 
al. 2012, Suen et al. 2010) suggest that small changes in gene expression in response to gliadin 
peptides are possible. It is evident that pepsin and trypsin affect gene transcription in vitro and 
under physiological conditions as the CelD biopsies were not exposed to exogenous pepsin and 
trypsin. Given that pepsin and trypsin were inactivated by heating, the in vitro effects on gene 
expression may be mediated by non-enzymatic epitopes of these proteases. Such effects have not 
been reported earlier and further investigations into the non-enzymatic effects of pepsin and trypsin 
are warranted. 
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Table 17. The pepsin and trypsin affected genes which are also affected by PT and/or PT-G are shown 
  
Suen et al. 
2010 
Johnston et al. 2012 Microarray 
Treatment Trypsin Pepsin Pepsin PT-G PT 
Gene/Cell type HEK 293 FaDu Primary Caco-2 Caco-2 
CDT1 0.8 
 
 0.8 0.8 
DUSP1 1.3 
 
 2.3 2.3 
DUSP10 0.9 
 
 1.3 1.3 
FOSL1 2 
 
 3.2 2.9 
ING4 0.7 
 
 0.7 0.7 
KLF5 1.6 
 
 1.8 1.7 
PTGS2 3.4 
 
 2 1.7 
PTPN14 1.4 
 
 1.3 1.3 
TSC22D3 0.4 
 
 1.3 1.3 
TXNIP 0.5 
 
 0.4 0.5 
GADD45A 1.4 
 
 1.3   
GADD45G 0.7 
 
 0.7   
GTF2H1 1.1 
 
 1.3   
NAB1 1.4 
 
 1.3   
NAB2 2.1 
 
 1.9   
KLF5 1.6 
 
 
 
2.1 
TERT 0.5 
 
 
 
0.7 
ETS2 
 
1.9 0.6 1.9 1.9 
BRCA1  0.3 0.5 0.8 0.7 
BAD  0.4 0.6  1.3 
BAX  0.5  1.4  
CDKN1A   0.6 2.4 2.6 
The data for trypsin and pepsin affected genes is obtained from previously published studies. The numbers 
represent fold change after respective treatment. HEK 293: Human embryonic kidney 293 cells, FaDu: squamous 
cell carcinoma cells (epithelial), Primary:  laryngeal primary epithelial cells, Caco-2: human colon carcinoma cells. 
 
Gliadin peptides have been reported to exert multiple effects on enterocytes. The most prominent 
and consistently reported effects are apoptosis, oxidative stress and proliferation. In a study by 
Giovannini et al., Caco-2 cells were exposed to PT-G, and an increased rate of apoptosis (30%) 
compared to the control cells was reported (Giovannini et al. 2000). In a follow-up study by the same 
group, it was suggested that enterocyte apoptosis induced by PT-G is through the Fas-FasL pathway 
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and can be inhibited using caspase-3 and caspase-8 inhibitors (Giovannini et al. 2003). Furthermore, 
incubation of Caco-2 cells with PT-G for six hours resulted in increased expression of the Fas and 
FasL genes. This study is similar to our study in experimental design, however, unlike Giovannini et 
al., no change in Fas/FasL gene expression after stimulation with PT-G or p31-43 peptide was 
observed in our study. A crucial difference between our study and the one by Giovannini et al. is the 
use of blank PT control in our study. It enabled us to filter out background genes, i.e. those affected 
by PT. Although Fas/FasL gene expression did not change in our experiments, the expression of the 
Fas-activated serine/threonine kinase (FASTK) gene, and the caspase 8 (CASP8) gene was down-
regulated in cells exposed to PT. The FASTK gene is rapidly activated in Fas-mediated apoptosis (Tian 
et al. 1995). Another pro-apoptosis gene, FAST kinase domain containing protein 2 (FASTKD2), was 
down-regulated by both PT and PT-G treatment. These data suggest that PT and PT-G exert anti-
apoptotic effect on epithelial cells.  In a similar experimental setup, Sakly et al. attempted to unravel 
the mechanism of gliadin toxicity to Caco-2 cells (Sakly et al. 2006). They found growth inhibitory 
effects of gliadin peptides on enterocytes which were not due to increased apoptosis or necrosis. As 
discussed in section 3.6, it is possible that increased apoptosis in enterocytes is a result of an 
interaction between FasL expressing IELs and Fas expressing enterocytes (Moss et al. 1996, Maiuri et 
al. 2001, Ciccocioppo et al. 2001). IL-15 has been shown to induce Fas expression on enterocytes 
(Maiuri et al. 2000) and apoptosis induced by gliadin and IL-15 can be abolished by anti-IL-15 
antibodies. These studies implicate the Fas-FasL pathway in enterocyte apoptosis which also 
requires the activation of LPMNCs to produce IL-15. Whether gliadin peptides can directly induce 
enterocyte apoptosis after six hours, independent of LPMNCs, remains controversial. 
IL-15 has also been implicated in enterocyte proliferation (Barone et al. 2011). Overnight stimulation 
of Caco-2 cells with gliadin peptides induces IL-15 gene transcription, which is highly dependent on 
pre-existing IL-15 in the cell (Barone et al. 2011). Shorter stimulations (three hours or six hours) did 
not result in an increase in IL-15 gene transcription. Our results are in line with this study as no 
change in the expression of IL-15 was observed after six hours, suggesting that a longer exposure 
time is required for this effect to take place. The gliadin p31-43 peptide was shown to accumulate in 
lysosomes for a prolonged period and induce cellular oxidative stress which eventually leads to the 
initiation of inflammatory responses (Luciani et al. 2009). Oxidative stress is known to activate the 
NFkB pathway and increased NFkB activity has been reported in CelD mucosa (Maiuri et al. 2003b, 
van den Berg et al. 2001). The observation that IL-15 production in rhinovirus infected macrophages 
is dependent on NFkB activation (Laza-Stanca et al. 2011) connects gliadin induced oxidative stress, 
IL-15 and proliferation.  It is conceivable that in epithelial cells, gliadin induces oxidative stress 
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followed by NFkB activation and IL-15 gene transcription. Given the role of IL-15 in enterocyte 
apoptosis and proliferation, this is an attractive hypothesis which warrants further studies.  
2. Association of rs601338-A-FUT2 with CelD, DH and IBD in the Finnish population 
The FUT2 gene encodes α-1,2-fucosyltransferase enzyme (Figure 5) which controls the expression of 
A-, B- and H- blood group antigens in mucus and other body secretions such as saliva and breast milk 
(Combs 2009). The secreted and expressed antigens in the gut control the composition of microbiota 
which in turn protects the host from pathogenic microbes and also affects the development of the 
mucosal immune system (Cieza et al. 2012, Shirato 2011, Makivuokko et al. 2012, Maynard et al. 
2012, Boren et al. 1993).  The FUT2 rs601338-AA genotype was associated with CelD in the Finnish 
population. Consistent with the role of FUT2 in affecting the composition of intestinal microbiota 
(Rausch et al. 2011), several studies have reported a shift in gut microbial communities in CelD 
patients compared to healthy individuals. Schippa et al. studied the mucosa-associated microbiota in 
a group of children with CelD and healthy controls (Schippa et al. 2010). Highly significant 
differences were found in the prevalence of B. vulgatus (85%) and E. coli (95%) in CelD patients 
compared to controls (20% in both cases). Differences in the gut microbial community between 
adult and pediatric CelD patients compared to each other and also compared to healthy controls 
have been reported (Nistal et al. 2011, Pozo-Rubio et al. 2012, Sanz, De Pama & Laparra 2011). 
Furthermore, changes in the intestinal microbial community have been shown to modulate mucosal 
immunity. De Palma et al. studied the effect of enterobacteria (E. coli CBL2 and Shigella CBD8) 
isolated from CelD patients, two strains of bifidobacteria and gliadin on phenotypic and functional 
features of monocyte derived dendritic cells (MDDCs) (De Palma et al. 2012). The results from this 
study showed that enterobacteria induced marked changes in MDDC morphology and induced an 
increase in the production of inflammatory cytokines (IFN-γ, TNF-α and IL-12). In contrast, these 
changes were seen to a much lesser extent in bifidobacteria exposed cells. The bifidobacteria also 
reduced gliadin-induced IFN-γ production and increased IL-10 secretion by MDDCs. Similarly, studies 
in rats kept under germ-free conditions show that E. coli CBL2 in combination with IFN-γ and gliadin 
leads to a reduction in the number of mucus-secreting goblet cells in the intestine (Cinova et al. 
2011). Taken together, these studies and the association of FUT2 non-secretor status with CelD 
suggest that FUT2 indirectly affects the risk for CelD by modulating gut microbiota and the immune 
system. An optimal composition of the gut microbiota may be particularly important in the 
childhood as multiple infections in early life are associated with increased risk for CelD (Myleus et al. 
2012). The use of antibiotics affects the gut microbiota. However, in a study by Myleus et al. no 
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significant association was found between antibiotic treatment in early childhood and increased risk 
for CelD (Myleus et al. 2012).   
In contrast to the association of FUT2 non-secretor status (rs601338-AA) with CelD, the association 
of rs601338-FUT2 with DH was not statistically significant (P > 0.05). DH is an extraintestinal 
manifestation of CelD and some patients do not experience gastrointestinal symptoms. Wacklin et 
al. investigated if differences in the composition of intestinal microbiota lead to different clinical 
manifestations of CelD, i.e. GI symptoms, DH, anemia or mixed symptoms (Wacklin et al. 2013). This 
study reported differences in mucosal microbial diversity and composition in CelD patients with GI 
symptoms and anemia compared to healthy controls. However, the microbial composition and 
diversity in DH patients was similar to that of controls. It is of note that in our study both, the 
frequency of non-secretors in the DH and CelD group (DH: 18.1% and CelD: 18%) and the effect sizes 
(OR) in both groups (DH: 1.29 and CelD: 1.28) were very similar. This suggests that the non-secretor 
status may be associated with DH also. It is likely that the lack of association with DH in our study 
may be due to lack of power in the DH group owing to fewer patients. This is further supported by 
the association of the rs601338-AA genotype of the FUT2 gene with the combined CelD + DH group 
which had several times more patients than the DH group alone. The association in the CelD + DH 
group showed stronger statistical significance (P=0.006), whereas the effect size (OR: 1.28) remained 
comparable. But given that the gut microbiota richness and diversity between CelD patients with GI 
symptoms and those with DH was similar, the role of the FUT2 polymorphisms in DH is unclear.    
Rausch et al. conducted a study where they investigated the composition of gut microbiota in CD 
patients and healthy subjects conditioned on FUT2 secretor and non-secretor status (Rausch et al. 
2011). There was a general change in the composition of the gut-associated microbial community in 
CD patients compared to healthy subjects. In addition, there were also significant secretor-status-
dependent differences in microbiota composition providing some evidence that FUT2 affects the 
composition of gut microbiota and may even play a role in IBD pathogenesis. There are differences 
in the composition of gut microbiota in individuals with CD and UC compared to healthy individuals 
and also between both disease groups (Andoh et al. 2011, Sokol et al. 2006, Dicksved et al. 2008, 
Willing et al. 2009). The association of rs601338-AA with CD and a lack of association of this SNP with 
UC has been reported in another population of European descent (McGovern et al. 2010b). 
However, we did not find any evidence for association of the FUT2 non-secretor genotype 
(rs601338-AA) with CD. The dissimilarity between our results and those obtained by McGovern et al. 
may depend upon differences in the studied populations, in the microbial species involved or on 
genetics. The CD susceptibility gene NOD2 has been shown to affect the composition of gut 
83 
 
microbiota, both in mice and humans (Li et al. 2012, Rehman et al. 2011, Petnicki-Ocwieja et al. 
2009) and several population-specific mutations in the NOD2 gene in the Finnish population have 
been identified (Lappalainen et al. 2008). It is plausible that different gene/genes affects/affect the 
gut microbial diversity and richness in the Finnish population. It is also conceivable that the gut 
microbiota at steady-state is a result of an interaction between products of different genetic variants 
of multiple genes. In addition, the lack of association may also be attributed to fewer patients in the 
CD group. Interestingly, there was some evidence for the association of rs601338-AA genotype (non-
secretor status) with protection (OR: 0.82) from UC. Under the dominant association model, this 
suggests that the rs601338-A allele confers protection against UC. A similar mode of association was 
evident in the combined UC + CD (OR: 0.84) dataset. The secretor status, defined by the FUT2 A385T 
variant, has been associated with increased risk for CD in the Japanese population (Miyoshi et al. 
2011), but a similar association with UC has not been reported in any population. In the study be 
McGovern et al., the FUT2 non-secretor status was associated with increased risk for CD but no 
association with UC was found (McGovern et al. 2010b). Our results are in stark contrast to these 
findings. The reason for differential association of the non-secretor status (rs601338-AA) with UC 
and CD between the two studies is most likely due to genetic differences between the studied 
populations. It is also possible that there are multiple common factors which influence the risk for 
UC or CD. Enrichment of certain factors in a population may confer increased risk for UC or CD in 
that population. Thus, having a certain genotype at one locus may not be a decisive factor in disease 
susceptibility. Association studies in different populations are required to further understand the 
role of secretor/non-secretor status in IBD susceptibility.  
3. Several CelD susceptibility genes also affect the risk for IBD.  
The association of some CelD risk loci with IBD in the Finnish population suggests some overlap in 
genetic predisposition. The genetic regions harboring the ICOSLG and PTPN2 genes were associated 
with both CD and UC in the Finnish population, but did not reach statistical significance after 
correcting for the number of tests (i.e. PEMP2 > 0.05). The product of the ICOSLG gene is expressed on 
APCs, B cells and endothelial cells and it serves as a ligand for inducible costimulator (ICOS) 
molecule, expressed on T cells. When a MHC bound foreign antigen is presented by APCs to antigen-
specific T cells, an interaction between ICOS and ICOSLG is crucial for the proper activation of T cells 
in response to the antigen. The association of ICOSLG with CD and UC has been demonstrated in 
other populations previously (Anderson et al. 2011, Franke et al. 2010). The lack of statistical 
significance for this association with CD and UC in our dataset is likely due to small sample size. The 
rs1893217-PTPN2 region was also nominally associated with CD location (left or right colitis) and 
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type (penetrating and fistulising) and with pediatric UC and with UC extensive colitis (Publication III, 
Table 2). An inappropriate immune response to gut-resident microbes has been implicated in 
mucosal inflammation in CD and UC. Recently, the PTPN2 gene was shown to be important in the 
maintenance of the gut epithelial barrier and the modulation of innate immune responses to 
bacterial antigens (McCole 2012, Scharl et al. 2012). Furthermore, genetic variants within the PTPN2 
gene have been associated with susceptibility to both UC and CD in the German population (Glas et 
al. 2012). In addition, a SNP, different from the one in our study, in the PTPN2 harboring genomic 
region was associated with the stricturing phenotype in CD. Interestingly, an epistatic interaction 
was observed in UC between a SNP tagging the CD gene ATG16L1 and a PTPN2-tagging SNP. In a 
population-specific manner, a genetic variant (rs2542151-G) in the PTPN2 region has been 
associated with increased risk for UC in the Chinese population, whereas the other allele of the same 
marker (rs2542151-A) was associated with increased risk for CD in the Italian population (Latiano et 
al. 2011). These studies suggest a role for PTPN2 in both UC and CD susceptibility but in a 
population-specific manner. The association of rs1893217-PTPN2 in the Finnish population may be a 
true association although it did not reach statistical significance (PEMP2 > 0.05) due to a smaller 
sample size. Similarly the ICOSLG gene tagging SNP was associated with multiple subphenotypes of 
both CD and UC, but did not reach statistical significance (PEMP2 > 0.05) after multiple testing 
correction. These associations are thus interesting, but require validation in a larger cohort of 
Finnish IBD patients. In the UC subphenotype meta-analysis of Finnish and Swedish datasets, 
rs4819388-ICOSLG was significantly associated with sporadic UC (Table 15) and this association 
remained significant (PEMP2 < 0.05) after correcting for the number of markers used in the analysis.  
A SNP (rs6974491-ELMO1) on chromosome seven showed strong association with pediatric UC (OR: 
2.20, PEMP2 < 0.05) and was also nominally associated with left-sided colitis in UC in the Finnish 
population (Publication III, Table 2). Furthermore, rs6974491-ELMO1 was also associated with 
pediatric UC (OR: 1.73, PEMP2 < 0.05) in the Finnish-Swedish UC subphenotype meta-analysis. ELMO1 
is involved in the phagocytosis of apoptotic cells and changes in the cell shape (van Ham, Kokel & 
Peterson 2012, Elliott et al. 2010). It is already well established that genes involved in autophagy 
(NOD2, IRGM, ATG16L1) contribute to the pathogenesis of CD (Rioux et al. 2007, Cooney et al. 2010). 
Furthermore, in an association study of IRGM variants with UC in the German population, Glas et al. 
also found weak, but statistically significant, association of several IRGM haplotypes with UC 
susceptibility (Glas et al. 2013). The association of ELMO1 with UC is interesting because studies on 
microbiota composition in UC patients report an overrepresentation of pathogenic bacteria 
(Escherichia/Shigella) in the gut (Lepage et al. 2011) and Shigella has been shown to use the ELMO1-
Dock180 complex for entry into epithelial cells (Handa et al. 2007). It is possible that certain ELMO1 
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genetic variants promote infection by Shigella leading to epithelial damage and activation of the 
immune system. The delineation of this mechanism requires further studies. Nevertheless, 
association of IRGM and ELMO1 variants with UC suggest that autophagy may also contribute to UC 
pathogenesis to some extent.  
The rs2298428 marker SNP lies within the YDJC gene on chromosome 22 and causes a missense 
mutation in this gene. Although this marker did not associate with CD/UC in the Finnish population, 
in the Finnish CD subphenotype meta-analysis, it was strongly (OR: 2.59, PEMP2 < 0.005) associated 
with pediatric CD (Publication III, Table 2). A less significant association (OR: 1.66, PEMP2 < 0.05) was 
also observed with the non-stricturing and non-penetrating phenotype of CD. Distinct genetic 
variants in this region are associated with different immunological diseases, such as rheumatoid 
arthritis (Zhernakova et al. 2011), cutaneous systemic sclerosis (Hasebe et al. 2012) and SLE (Wang 
et al. 2012). Despite association of this region with multiple diseases, the role of the YDJC gene 
remains poorly understood in disease pathogenesis. The rs2298428 marker lies in the vicinity of the 
UBE2L3 gene. Interestingly, in a study by Fransen et al. (Fransen et al. 2010) the SNP rs2298428-T-
UBE2L3 was associated with higher expression levels of the UBE2L3 gene in the Dutch population. 
However, in another study investigating common susceptibility loci between CelD and CD, genetic 
variants within the UBE2L3 gene were not associated with CD in the Dutch population (Festen et al. 
2011). It should however be noted that, in the Finnish IBD dataset, rs2298428-T did not associate 
with CD or UC but only with specific subphenotypes of these diseases. A lack of association in the 
whole CD dataset in our study and that by Festen et al. suggests that this SNP confers susceptibility 
in a phenotype-specific manner. The UBE2L3 gene encodes an ubiquitin-conjugating enzyme and its 
functional role in IBD is not clear. Nonetheless, it may be an interesting risk gene in IBD as it may 
have a role in modulating the NFkB pathway as suggested by Fransen et al. (Fransen et al. 2010).  
Two SNPs (rs9295089 and rs1738074) in the genomic region harboring the TAGAP gene were 
investigated for their association with IBD. The TAGAP gene encodes T-cell activation GTPase-
activating protein, but the functional role of this protein has not been confirmed. The two SNPs in 
the genomic locus harboring the TAGAP gene are located close to each other on chromosome six 
and are in LD (D’ = 1, r2 = 0.19). The SNP marker rs1738074 was found to yield the strongest 
association signal in the multi-population analysis performed in the CelD GWAS by Dubois et al. 
(Dubois et al. 2010). Interestingly, different association patterns were observed for the two SNPs 
(Publication III, Table 1 and Table 2). Although neither of the SNPs was associated with CD or UC in 
general, rs9295089-C and rs1738074-T were associated with increased risk of several CD and/or UC 
subphenotypes, respectively. rs9295089-C was associated with increased risk (OR: 1.48- 1-87) for 
86 
 
CD-subphenotypes, such as ileocolonic CD and extensive colitis, whereas rs1738074 was associated 
with protection (OR: 0.63) from UC in patients with a family history of UC. Neither of the SNPs was 
significant (PEMP2 > 0.05) after correcting for the number of markers used in the analysis. However, in 
the Finnish-Swedish UC meta-analysis, rs1738074-T was associated with protection (OR: 0.83) from 
UC and remained statistically significant (PEMP2 < 0.05) after correcting for the number of markers. 
Similarly, in the Finnish-Swedish UC subphenotype meta-analysis, rs1738074-T showed strong 
protective (OR: 0.61 and PEMP2 < 0.005) association with familial UC. These results suggest that 
rs1738074-T confers protection against familial UC. In the CelD GWAS (Dubois et al. 2010), this SNP 
was associated with increased risk for CelD. The same genetic variants thus appear to have opposing 
effects on risk for different diseases. A genetic variant (rs2451258-C) in the TAGAP gene has been 
associated with increased risk for psoriasis (Tsoi et al. 2012). In contrast, rs1738074-T confers 
protection against multiple sclerosis (Patsopoulos et al. 2011) and T1D (Smyth et al. 2008). In 
addition other genetic variants in the TAGAP gene have been associated with protection against 
rheumatoid arthritis (Eyre et al. 2010) and anal sepsis in ileocolonic CD (Connelly et al. 2012). Taken 
together, our results and previous studies suggest that the TAGAP is a common susceptibility gene 
for several diseases. Furthermore, it is also highlighted that genes or genetic variants conferring 
susceptibility to one disease may be protective in another disease in a population-dependent 
manner.  
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Conclusions and future directions 
In the first study of this thesis, the effect of gliadin peptides, the environmental trigger in CelD, on 
epithelial cell gene transcription was investigated. This study was undertaken as a result of previous 
studies suggesting direct effects of certain gliadin-derived peptides on enterocytes (Giovannini et al. 
2003, Luciani et al. 2009, Sakly et al. 2006, Rivabene, Mancini & De Vincenzi 1999, Rivabene, Mancini 
& De Vincenzi 1999, Dolfini et al. 2002). In this study, a gene expression profile of Caco-2 cells 
exposed to PT-G and p31-43 peptide was obtained. Several genes were differentially regulated after 
stimulation with PT-G. However, they were also affected by the negative controls PT, PT-BSA and PT-
L, suggesting that pepsin- and trypsin- derived peptides may affect, directly or indirectly, enterocyte 
gene transcription. This hypothesis gets support from previous studies (Johnston et al. 2012, Suen et 
al. 2010) as many genes differentially expressed after PT-G treatment are also differentially 
expressed after exposure to pepsin and trypsin. However, further studies on the role of pepsin and 
trypsin on enterocyte gene expression were beyond the scope of this thesis work and separate 
studies should be conducted to ascertain their role. In addition, the results suggest that gliadin may 
induce small differences in gene transcription. This may be particularly true for the p31-43 peptide 
as the microarray results could not be verified by qRT-PCR for any of the selected genes. The results 
from this study also suggest that most gliadin mediated effects in CelD may require the presence of 
other effector cells and chemical mediators. Based on the results obtained in this study, it is 
concluded that gliadin peptides alone have only small effects on enterocyte gene expression. The 
changes that gliadin peptides induce in gut epithelial cells of CelD patient are suggested to be a 
result of interactions between the immune system and gliadin peptides and it cannot be concluded 
that gliadin does not affect enterocyte gene transcription. An enterocyte gene expression study 
which also considers the possible effects of pepsin and trypsin and includes proper controls is thus 
highly recommended.  
In the second study of this thesis, the association of rs601338-FUT2 with CelD, DH, CD, UC and IBD in 
the Finnish population was investigated. We found evidence for association of the rs601338-AA 
genotype with increased risk for CelD, but not with DH, most likely due to a small sample size. In 
contrast, no evidence for rs601338-A association with IBD was found. We conclude that the FUT2 
non-secretor status (rs601338-AA) is associated with CelD but not with IBD in the Finnish population. 
The future course of research in this field should be to investigate how FUT2 defined gut microbiota 
affects the development of the immune system, subsequently affecting the risk of an individual to 
develop autoimmune diseases. 
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The third study focused on identifying which of the genetic variants that confer susceptibility to CelD 
also affect the risk of IBD in the Finnish and Swedish population.  
Our results demonstrate that several CelD risk genes also confer susceptibility to IBD in the Finnish 
and the Swedish population. Some genes were associated with a particular disease subphenotype 
(e.g. familial UC, early onset UC/CD etc.) rather than with the disease in general (e.g. TAGAP, ELMO1 
and UBE2L3). To conclude, several CelD risk loci were found to be associated with CD and/or UC or 
their associated subphenotypes in the Finnish and Swedish population. Furthermore, we show that 
the division of study subjects into different groups is useful for the identification of genes conferring 
susceptibility to a particular disease subphenotype, albeit it may lead to smaller sample sizes. To 
divide study subjects in subgroups based on their disease phenotype is an effective strategy for 
identifying phenotype-specific genes. However, the associated genes may not reach statistical 
significance after multiple testing corrections. Thus, future studies with a similar study design but 
larger datasets are recommended. If the sample sizes become large enough, one might consider 
more interaction studies. The future genetic studies may be combined with different sequencing 
methods (RNA sequencing, exome sequencing) to identify causal variants. Linkage studies in families 
could be combined with sequencing methods to identify rare disease variants. Different families may 
have different mutations in different genes, but those genes may participate in or affect common 
pathways. 
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